text
stringlengths 102
112k
| url
stringlengths 37
240
| crawl_date
timestamp[us, tz=UTC]date 2024-01-04 00:15:18
2024-01-31 23:10:45
| exclusion_reason
stringclasses 1
value |
|---|---|---|---|
Etsy (ETSY - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this online crafts marketplace have returned -15.1%, compared to the Zacks S&P 500 composite's +3.1% change. During this period, the Zacks Internet - Services industry, which Etsy falls in, has gained 6.9%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Etsy is expected to post earnings of $0.78 per share, indicating a change of +1.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +3.5% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of $2.37 points to a change of -12.9% from the prior year. Over the last 30 days, this estimate has changed +1.7%.
For the next fiscal year, the consensus earnings estimate of $2.69 indicates a change of +13.7% from what Etsy is expected to report a year ago. Over the past month, the estimate has changed +1.5%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Etsy.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Etsy, the consensus sales estimate of $826.71 million for the current quarter points to a year-over-year change of +2.4%. The $2.73 billion and $2.86 billion estimates for the current and next fiscal years indicate changes of +6.5% and +4.8%, respectively.
Last Reported Results and Surprise History
Etsy reported revenues of $636.3 million in the last reported quarter, representing a year-over-year change of +7%. EPS of $0.64 for the same period compares with $0.58 a year ago.
Compared to the Zacks Consensus Estimate of $629.75 million, the reported revenues represent a surprise of +1.04%. The EPS surprise was +30.61%.
Over the last four quarters, Etsy surpassed consensus EPS estimates three times. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Etsy is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Etsy. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216409/here-is-what-to-know-beyond-why-etsy-inc-etsy-is-a-trending-stock
| 2024-01-26T18:56:11Z
|
blocked_url
|
It doesn't matter if you're a growth, value, income, or momentum-focused investor -- building a successful investment portfolio takes skill, research, and a little bit of luck.
But what's the best way to find the right combination of stocks? Because funding things like your retirement, your kids' college tuition, or your short- and long-term savings goals will definitely require significant returns.
Enter the Zacks Rank.
What is the Zacks Rank?
The Zacks Rank is a unique, proprietary stock-rating model that utilizes earnings estimate revisions to help investors build a winning portfolio.
There are four main factors behind the Zacks Rank: Agreement, Magnitude, Upside, and Surprise.
Agreement is the extent to which all brokerage analysts are revising their earnings estimates in the same direction. The greater the percentage of analysts revising their estimates higher, the better chance the stock will outperform.
Magnitude is the size of the recent change in the consensus estimate for the current and next fiscal years.
Upside is the difference between the most accurate estimate, which is calculated by Zacks, and the consensus estimate.
Surprise is made up of a company's last few quarters' earnings per share surprises; companies with a positive earnings surprise are more likely to beat expectations in the future.
Each factor is given a raw score, which is recalculated every night and compiled into the Zacks Rank. Utilizing this data, stocks are put into five different groups: Strong Buy, Buy, Hold, Sell, and Strong Sell.
The Power of Institutional Investors
The Zacks Rank also allows individual investors, or retail investors, to benefit from the power of institutional investors.
Institutional investors are the professionals who manage the trillions of dollars invested in mutual funds, investment banks, and hedge funds. Studies have shown that these investors can and do move the market due to the large amounts of money they invest with. Because of this, the market tends to move in the same direction as institutional investors.
In order to determine the fair value of a company and its shares, institutional investors design valuation models that focus on earnings and earnings estimates. Because if you raise earnings estimates, it then creates a higher fair value for a company and its stock price.
With these changes, institutional investors will act, usually buying stocks with rising estimates and selling those with falling estimates. An increase in earnings expectations can potentially lead to higher stock prices and bigger gains for the investor.
Because it can take a long time for an institutional investor to build a position -- sometimes weeks, if not months -- retail investors who get in at the first sign of upward revisions have a distinct advantage over these larger investors, and can benefit from the expected institutional buying that will follow.
Not only can the Zacks Rank help you take advantage of trends in earnings estimate revisions, but it can also provide a way to get into stocks that are highly sought after by professionals.
How to Invest with the Zacks Rank
The Zacks Rank is known for transforming investment portfolios. In fact, a portfolio of Zacks Rank #1 (Strong Buy) stocks has beaten the market in 26 of the last 32 years, with an average annual return of +25.41%.
Moreover, stocks with a new #1 (Strong Buy) ranking have some of the biggest profit potential, while those that fell to a #4 (Sell) or #5 (Strong Sell) have some of the worst.
Let's take a look at Honda Motor (HMC - Free Report) , which was added to the Zacks Rank #1 list on January 26, 2024.
Honda Motor Co., Ltd. is a leading manufacturer of automobiles and the largest producer of motorcycles in the world. The company is recognized internationally for its wide variety of products, ranging from small general-purpose engines to specialty sports cars, which incorporate its efficient internal combustion engine technologies.
Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.16 to $4.16 per share. HMC boasts an average earnings surprise of 26.9%.
Analysts are expecting earnings to grow 37.3% for the current fiscal year, with revenue forecasted to rise 14.8%.
Even more impressive, HMC has gained in value over the past four weeks, up 5.3% compared to the S&P 500's gain of 3.1%.
Bottom Line
With a #1 (Strong Buy) ranking, positive trend in earnings estimate revisions, and strong market momentum, Honda Motor should be on investors' shortlist.
If you want even more information on the Zacks Ranks, or one of our many other investing strategies, check out the Zacks Education home page.
Discover Today's Top Stocks
Our private Zacks #1 Rank List, based on our quantitative Zacks Rank stock-rating system, has more than doubled the S&P 500 since 1988. Applying the Zacks Rank in your own trading can boost your investing returns on your very next trade. See Today's Zacks #1 Rank List >>
|
https://www.zacks.com/stock/news/2216410/how-to-find-strong-buy-auto-tires-and-trucks-stocks-using-the-zacks-rank
| 2024-01-26T18:56:17Z
|
blocked_url
|
It doesn't matter if you're a growth, value, income, or momentum-focused investor -- building a successful investment portfolio takes skill, research, and a little bit of luck.
But how do you find the right combination of stocks? Funding your retirement, your kids' college tuition, or your short- and long-term savings goals certainly requires significant returns.
Enter the Zacks Rank.
What is the Zacks Rank?
The Zacks Rank, which is a unique, proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, that makes building a winning portfolio easier.
There are four main factors behind the Zacks Rank: Agreement, Magnitude, Upside, and Surprise.
Agreement is the extent to which all brokerage analysts are revising their earnings estimates in the same direction. The greater the percentage of analysts revising their estimates higher, the better chance the stock will outperform.
Magnitude is the size of the recent change in the consensus estimate for the current and next fiscal years.
Upside is the difference between the most accurate estimate, which is calculated by Zacks, and the consensus estimate.
Surprise is made up of a company's last few quarters' earnings per share surprises; companies with a positive earnings surprise are more likely to beat expectations in the future.
These four factors are assigned a raw score that's recalculated every night, which is then compiled into the ranking system. Stocks are classified into five groups using this data, ranging from "Strong Buy" to "Strong Sell."
The Power of Institutional Investors
The Zacks Rank also allows individual investors, or retail investors, to benefit from the power of institutional investors.
Institutional investors are responsible for managing the trillions of dollars invested in mutual funds, hedge funds, and investment banks. Research has shown that these investors can and do move the market due to the large amount of money they deal with, and thus, the market tends to move in the same direction as them.
These investors are known for designing valuation models that focus on earnings and earnings expectations in order to figure out the fair value of a company and its shares. If earnings estimates are raised, it puts a higher value on a company.
Institutional investors will use these changes to help in their decision-making, typically buying stocks with rising estimates and selling those with falling estimates. Higher earnings expectations can translate into a rise in stock price and bigger gains for the investor.
Since it can often take weeks, if not months, for an institutional investor to build a position (given their size), retail investors who get in at the first sign of upward earnings estimate revisions have a distinct advantage over these larger investors, and can benefit from the expected institutional buying that will follow.
Not only can the Zacks Rank help you take advantage of trends in earnings estimate revisions, but it can also provide a way to get into stocks that are highly sought after by professionals.
How to Invest with the Zacks Rank
The Zacks Rank is known for transforming investment portfolios. In fact, a portfolio of Zacks Rank #1 (Strong Buy) stocks has beaten the market in 26 of the last 32 years, with an average annual return of +25.41%.
Moreover, stocks with a new #1 (Strong Buy) ranking have some of the biggest profit potential, while those that fell to a #4 (Sell) or #5 (Strong Sell) have some of the worst.
Let's take a look at Netflix (NFLX - Free Report) , which was added to the Zacks Rank #1 list on January 25, 2024.
Netflix is considered a pioneer in the streaming space. The company evolved from a small DVD-rental provider to a dominant streaming service provider, courtesy of its wide-ranging content portfolio and a fortified international footprint. At the end of the fourth quarter of 2023, the company had 260.28 million paid subscribers globally.
For fiscal 2024, 11 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.80 to $16.73 per share. NFLX boasts an average earnings surprise of 5.4%.
Analysts are expecting earnings to grow 39.1% for the current fiscal year, with revenue forecasted to rise 14.2%.
NFLX has been moving higher over the past four weeks as well, up 14.6% compared to the S&P 500's gain of 3.1%.
Bottom Line
With a #1 (Strong Buy) ranking, positive trend in earnings estimate revisions, and strong market momentum, Netflix should be on investors' shortlist.
If you want even more information on the Zacks Ranks, or one of our many other investing strategies, check out the Zacks Education home page.
Discover Today's Top Stocks
Our private Zacks #1 Rank List, based on our quantitative Zacks Rank stock-rating system, has more than doubled the S&P 500 since 1988. Applying the Zacks Rank in your own trading can boost your investing returns on your very next trade. See Today's Zacks #1 Rank List >>
|
https://www.zacks.com/stock/news/2216411/the-zacks-rank-explained-how-to-find-strong-buy-consumer-discretionary-stocks
| 2024-01-26T18:56:18Z
|
blocked_url
|
United Bankshares (UBSI - Free Report) came out with quarterly earnings of $0.66 per share, missing the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -1.49%. A quarter ago, it was expected that this holding company for United Bank would post earnings of $0.66 per share when it actually produced earnings of $0.71, delivering a surprise of 7.58%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
United Bankshares
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
United Bankshares shares have lost about 1.6% since the beginning of the year versus the S&P 500's gain of 2.6%.
What's Next for United Bankshares?
While United Bankshares has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for United Bankshares: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.63 on $255.35 million in revenues for the coming quarter and $2.58 on $1.04 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Southeast is currently in the top 23% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
First Reliance Bancshares Inc. (FSRL - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2023.
This company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of -5.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
First Reliance Bancshares Inc.'s revenues are expected to be $9.25 million, down 1.8% from the year-ago quarter.
|
https://www.zacks.com/stock/news/2216412/united-bankshares-ubsi-misses-q4-earnings-estimates
| 2024-01-26T18:56:25Z
|
blocked_url
|
Alliant Energy Corporation’s (LNT - Free Report) strategic investments in natural gas projects and stable returns from regulated assets will further drive its bottom line. The company’s focus on electricity generated from clean assets will help serve its expanding customer base.
However, Alliant Energy’s dependence on third-party assets for transmission acts as a headwind.
Tailwinds
LNT plans to invest substantially over the next four years to strengthen the electric and gas distribution network as well as add natural gas and renewable assets to its generation portfolio. It expects investments of $9.1 billion during 2024-2027. Its strong and flexible investment plans will support an 8% base CAGR during the same period.
The company’s earnings prospects look attractive due to the ongoing additions to electric and natural gas customer volumes. Its geographic location and favorable regulatory developments bode well for the advancement of wind projects and LNT’s long-term earnings growth. The ongoing economic growth in its service territories and increasing customer base are also boosting its performance and creating fresh demand for utility services.
Alliant Energy is successfully completing major construction projects on time and at or below budget. A constructive regulatory environment will enable it to recover capital expenditures. The company continues to be the largest owner-operator of solar energy in Wisconsin. It has all solar sites and panels in control for its planned 1.1 gigawatts (GW) of utility-scale solar projects within the state by mid-2024. LNT placed 250 megawatts (MW) of solar capacity into service and expects to add an additional 840 MW by mid-2024.
Headwinds
The company’s utility operations — IPL and WPL — use the interstate electric transmission system that they do not own or control. Rates charged to these subsidiaries are regulated by FERC. In case transmission costs go up and LNT is unable to recover those costs from its customers, operational expenses are bound to rise. A fall in the performance of the third-party electric transmission system will limit Alliant Energy’s ability to transmit electricity within its service territories and adversely impact its operations.
Transition in Energy Space
The U.S. electric power sector is gradually moving toward cleaner sources of energy to produce electricity. Most of the companies target replacing fossil fuels with renewables and believe in the development of new technologies. They have pledged to deliver 100% clean energy and achieve the zero-emission target in the coming years.
To reap the benefits of the expanding renewable energy market, certain companies from the industry, such as Xcel Energy Inc. (XEL - Free Report) , PPL Corp. (PPL - Free Report) and Dominion Energy (D - Free Report) are also transitioning faster toward clean energy.
Xcel Energy aims to spend $34 billion during the 2024-2028 period, indicating an increase of $4.5 billion from its previous capital expenditure plan. These investments are aimed at strengthening and expanding XEL’s transmission, distribution, electric generation and renewable projects.
It is reducing coal usage and targets to lower emissions by at least 80% by 2030 and achieve carbon neutrality by 2050. After completing six wind projects with a combined capacity of 1,500 MW in 2020, the company completed four wind farms, adding another 800 MW of clean energy generation capacity to its portfolio.
PPL’s strategic investments will expand its renewable-generation capacity. PPL expects a regulated capital investment plan of $12 billion through 2026.
PPL plans to achieve its carbon emission target of 70% and 80% by 2035 and 2040, respectively, from its 2010 level. It will do so through the introduction of new carbon capture technology and addition of more renewable sources to the generation portfolio. It also aims to become carbon neutral by 2050.
Dominion Energy has a well-chalked-out long-term capital expenditure plan to strengthen and expand its infrastructure. It expects to make a capital investment of $9 billion annually through 2025.
Dominion Energy’s long-term objective is to add 24 GW of battery storage, solar, hydro and wind (offshore as well as onshore) projects by 2036 and increase the renewable energy capacity by more than 15% per year, on average, over the next 15 years. It plans to invest $42 billion in offshore wind and solar projects during 2022-2035 to further expand its renewable operations.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
PPL Corporation (PPL) - free report >>
Xcel Energy Inc. (XEL) - free report >>
|
https://www.zacks.com/stock/news/2216413/alliant-energy-lnt-rides-on-investments-renewable-expansion
| 2024-01-26T18:56:31Z
|
blocked_url
|
The upcoming report from Aflac (AFL - Free Report) is expected to reveal quarterly earnings of $1.47 per share, indicating an increase of 14% compared to the year-ago period. Analysts forecast revenues of $4.44 billion, representing an increase of 10.8% year over year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.9% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Aflac metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Revenues- Other income (loss)' of $44.29 million. The estimate indicates a change of -11.4% from the prior-year quarter.
Analysts forecast 'Revenues- Net investment income' to reach $904.81 million. The estimate indicates a year-over-year change of +1%.
According to the collective judgment of analysts, 'Revenues- Total net earned premiums' should come in at $3.41 billion. The estimate indicates a change of -4.8% from the prior-year quarter.
The average prediction of analysts places 'Total adjusted revenues- Aflac Japan' at $2.54 billion. The estimate indicates a year-over-year change of -8.4%.
Analysts expect 'Revenues- Aflac Japan- Total net earned premiums' to come in at $1.90 billion. The estimate indicates a year-over-year change of -12.4%.
Based on the collective assessment of analysts, 'Revenues- Aflac Japan- Net investment income' should arrive at $636.43 million. The estimate suggests a change of +0.7% year over year.
Analysts' assessment points toward 'Revenues- Aflac U.S.- Other income' reaching $33.93 million. The estimate indicates a year-over-year change of -17.2%.
It is projected by analysts that the 'Total adjusted revenues- Aflac U.S.' will reach $1.67 billion. The estimate points to a change of +3.1% from the year-ago quarter.
Analysts predict that the 'Tot. Ben. /Premium - Aflac Japan' will reach 66.5%. Compared to the present estimate, the company reported 66.2% in the same quarter last year.
The consensus estimate for 'Tot. Adj. Expenses/Total Adj. Rev. - Aflac U.S.' stands at 41.5%. The estimate compares to the year-ago value of 44%.
The combined assessment of analysts suggests that 'Tot. Ben. /Premium - Aflac U.S.' will likely reach 47.1%. The estimate is in contrast to the year-ago figure of 40.8%.
The consensus among analysts is that 'Tot. Adj. Expenses/Total Adj. Rev. - Aflac Japan' will reach 21.4%. The estimate compares to the year-ago value of 22.9%.
View all Key Company Metrics for Aflac here>>>
Shares of Aflac have experienced a change of +3.4% in the past month compared to the +3.1% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), AFL is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216414/what-analyst-projections-for-key-metrics-reveal-about-aflac-afl-q4-earnings
| 2024-01-26T18:56:37Z
|
blocked_url
|
Wall Street analysts expect Otis Worldwide (OTIS - Free Report) to post quarterly earnings of $0.85 per share in its upcoming report, which indicates a year-over-year increase of 13.3%. Revenues are expected to be $3.57 billion, up 3.9% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Otis Worldwide metrics that are routinely monitored and predicted by Wall Street analysts.
It is projected by analysts that the 'Net Sales- Service' will reach $2.09 billion. The estimate indicates a change of +5.5% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- New Equipment' will reach $1.49 billion. The estimate points to a change of +1.9% from the year-ago quarter.
Analysts expect 'Adjusted Operating Profit- New Equipment' to come in at $104.55 million. The estimate is in contrast to the year-ago figure of $72 million.
Analysts' assessment points toward 'Adjusted Operating Profit- Service' reaching $499.52 million. The estimate is in contrast to the year-ago figure of $472 million.
View all Key Company Metrics for Otis Worldwide here>>>
Shares of Otis Worldwide have demonstrated returns of -0.8% over the past month compared to the Zacks S&P 500 composite's +3.1% change. With a Zacks Rank #4 (Sell), OTIS is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216415/countdown-to-otis-worldwide-otis-q4-earnings-wall-street-forecasts-for-key-metrics
| 2024-01-26T18:56:39Z
|
blocked_url
|
Wall Street analysts expect Cencora (COR - Free Report) to post quarterly earnings of $2.85 per share in its upcoming report, which indicates a year-over-year increase of 5.2%. Revenues are expected to be $68.81 billion, up 9.5% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Cencora metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts forecast 'Revenue- Total International Healthcare Solutions' to reach $7.07 billion. The estimate suggests a change of +7% year over year.
According to the collective judgment of analysts, 'Revenue- Total U.S. Healthcare Solutions' should come in at $61.65 billion. The estimate points to a change of +9.6% from the year-ago quarter.
The consensus among analysts is that 'Revenue- International Healthcare Solutions- Alliance Healthcare' will reach $5.86 billion. The estimate points to a change of +7.4% from the year-ago quarter.
It is projected by analysts that the 'Revenue- U.S. Healthcare Solutions- Animal Health' will reach $1.42 billion. The estimate suggests a change of +22.3% year over year.
The consensus estimate for 'Revenue- U.S. Healthcare Solutions- Human Health' stands at $59.85 billion. The estimate suggests a change of +8.7% year over year.
Based on the collective assessment of analysts, 'Revenue- International Healthcare Solutions- Other Healthcare Solutions' should arrive at $1.18 billion. The estimate indicates a year-over-year change of +2.3%.
The collective assessment of analysts points to an estimated 'Operating income- Non-GAAP- International Healthcare Solutions' of $166.10 million. Compared to the current estimate, the company reported $161.28 million in the same quarter of the previous year.
Analysts expect 'Operating income- Non-GAAP- U.S. Healthcare Solutions' to come in at $613.16 million. Compared to the present estimate, the company reported $572.42 million in the same quarter last year.
View all Key Company Metrics for Cencora here>>>
Over the past month, shares of Cencora have returned +7.5% versus the Zacks S&P 500 composite's +3.1% change. Currently, COR carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216416/unlocking-q1-potential-of-cencora-cor-exploring-wall-street-estimates-for-key-metrics
| 2024-01-26T18:56:45Z
|
blocked_url
|
In its upcoming report, Boston Scientific (BSX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.51 per share, reflecting an increase of 13.3% compared to the same period last year. Revenues are forecasted to be $3.59 billion, representing a year-over-year increase of 10.7%.
The current level reflects an upward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Boston Scientific metrics that are routinely monitored and predicted by Wall Street analysts.
Based on the collective assessment of analysts, 'Net Sales- Cardiovascular- Worldwide' should arrive at $2.19 billion. The estimate points to a change of +9.2% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- MedSurg- Worldwide' will reach $1.40 billion. The estimate points to a change of +8.1% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Cardiovascular- Cardiology- Worldwide' reaching $1.66 billion. The estimate points to a change of +8.4% from the year-ago quarter.
The consensus estimate for 'Net Sales- MedSurg- Urology- Worldwide' stands at $506.68 million. The estimate indicates a year-over-year change of +6.2%.
Analysts forecast 'Net Sales- Cardiovascular- Interventional Cardiology Therapies- United States' to reach $176.49 million. The estimate indicates a change of +0.3% from the prior-year quarter.
The average prediction of analysts places 'Geographic Revenue- U.S.' at $2.13 billion. The estimate suggests a change of +7.4% year over year.
The combined assessment of analysts suggests that 'Net Sales- Cardiovascular- Peripheral Interventions- United States' will likely reach $282.94 million. The estimate indicates a year-over-year change of +6.4%.
According to the collective judgment of analysts, 'Net Sales- Cardiovascular- Peripheral Interventions- International' should come in at $248.69 million. The estimate suggests a change of +18.4% year over year.
Analysts expect 'Net Sales- MedSurg- Neuromodulation- United States' to come in at $201.23 million. The estimate points to a change of +2.7% from the year-ago quarter.
It is projected by analysts that the 'Net Sales- MedSurg- Neuromodulation- International' will reach $57.04 million. The estimate points to a change of +7.6% from the year-ago quarter.
Analysts predict that the 'Net Sales- MedSurg- Endoscopy- United States' will reach $385.14 million. The estimate indicates a change of +10.4% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net Sales- MedSurg- Endoscopy- International' of $253.63 million. The estimate suggests a change of +13.7% year over year.
View all Key Company Metrics for Boston Scientific here>>>
Over the past month, shares of Boston Scientific have returned +8.1% versus the Zacks S&P 500 composite's +3.1% change. Currently, BSX carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216417/boston-scientific-bsx-q4-earnings-preview-what-you-should-know-beyond-the-headline-estimates
| 2024-01-26T18:56:51Z
|
blocked_url
|
In its upcoming report, Nasdaq (NDAQ - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.69 per share, reflecting an increase of 7.8% compared to the same period last year. Revenues are forecasted to be $1.06 billion, representing a year-over-year increase of 17.4%.
The current level reflects a downward revision of 0.5% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Nasdaq metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Total industry average daily share volume - Cash Equity Trading' will likely reach 11.15 billion. Compared to the current estimate, the company reported 11.2 billion in the same quarter of the previous year.
The consensus among analysts is that 'Total matched market share executed on Nasdaq exchanges - Cash Equity Trading' will reach 16.7%. The estimate is in contrast to the year-ago figure of 17.3%.
It is projected by analysts that the 'Total industry average daily volume - Equity Derivative Trading and Clearing' will reach 40.02 million. The estimate is in contrast to the year-ago figure of 39.3 million.
Analysts predict that the 'Total matched market share executed on Nasdaq exchanges - Equity Derivative Trading and Clearing' will reach 31.3%. The estimate compares to the year-ago value of 31.9%.
View all Key Company Metrics for Nasdaq here>>>
Over the past month, shares of Nasdaq have returned +0.2% versus the Zacks S&P 500 composite's +3.1% change. Currently, NDAQ carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216418/what-analyst-projections-for-key-metrics-reveal-about-nasdaq-ndaq-q4-earnings
| 2024-01-26T18:56:57Z
|
blocked_url
|
The upcoming report from A.O. Smith (AOS - Free Report) is expected to reveal quarterly earnings of $0.95 per share, indicating an increase of 10.5% compared to the year-ago period. Analysts forecast revenues of $982.51 million, representing an increase of 5% year over year.
The current level reflects an upward revision of 2.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific A.O. Smith metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Geographic Revenue- North America' stands at $730.84 million. The estimate indicates a year-over-year change of +5.6%.
According to the collective judgment of analysts, 'Geographic Revenue- Rest of World' should come in at $257.24 million. The estimate indicates a change of +3% from the prior-year quarter.
Based on the collective assessment of analysts, 'Segment Operating Earnings (GAAP)- Rest of World' should arrive at $27.37 million. Compared to the present estimate, the company reported $31.60 million in the same quarter last year.
Analysts forecast 'Segment Operating Earnings (NON-GAAP)- North America' to reach $182.87 million. Compared to the current estimate, the company reported $161.20 million in the same quarter of the previous year.
The consensus among analysts is that 'Segment Operating Earnings (NON-GAAP)- Rest of World' will reach $25.86 million. The estimate compares to the year-ago value of $31.60 million.
View all Key Company Metrics for A.O. Smith here>>>
Shares of A.O. Smith have demonstrated returns of -1.2% over the past month compared to the Zacks S&P 500 composite's +3.1% change. With a Zacks Rank #3 (Hold), AOS is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216419/curious-about-ao-smith-aos-q4-performance-explore-wall-street-estimates-for-key-metrics?-explore-wall-street-estimates-for-key-metrics
| 2024-01-26T18:56:59Z
|
blocked_url
|
The upcoming report from Old Dominion Freight Line (ODFL - Free Report) is expected to reveal quarterly earnings of $2.86 per share, indicating a decline of 2.1% compared to the year-ago period. Analysts forecast revenues of $1.5 billion, representing an increase of 0.9% year over year.
The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Old Dominion metrics that are commonly monitored and projected by Wall Street analysts.
The consensus among analysts is that 'Operating Ratio' will reach 72.1%. The estimate compares to the year-ago value of 71.2%.
The consensus estimate for 'LTL tonnage per day' stands at 38.21 Kton/D. Compared to the present estimate, the company reported 38.2 Kton/D in the same quarter last year.
It is projected by analysts that the 'LTL revenue per hundredweight' will reach $32.21. Compared to the present estimate, the company reported $31.30 in the same quarter last year.
Analysts expect 'LTL revenue per hundredweight, excluding fuel surcharges' to come in at $26.50. Compared to the current estimate, the company reported $24.65 in the same quarter of the previous year.
The collective assessment of analysts points to an estimated 'Work days' of 61.00 Days. The estimate compares to the year-ago value of 61 Days.
The combined assessment of analysts suggests that 'LTL weight per shipment (lbs.)' will likely reach 1,513.93 lbs. Compared to the present estimate, the company reported 1,565 lbs in the same quarter last year.
Analysts forecast 'LTL shipments' to reach 2,999. The estimate compares to the year-ago value of 2,977.
View all Key Company Metrics for Old Dominion here>>>
Over the past month, Old Dominion shares have recorded returns of -3.8% versus the Zacks S&P 500 composite's +3.1% change. Based on its Zacks Rank #3 (Hold), ODFL will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216420/unveiling-old-dominion-odfl-q4-outlook-wall-street-estimates-for-key-metrics
| 2024-01-26T18:57:05Z
|
blocked_url
|
Wall Street analysts forecast that Fortive (FTV - Free Report) will report quarterly earnings of $0.93 per share in its upcoming release, pointing to a year-over-year increase of 5.7%. It is anticipated that revenues will amount to $1.57 billion, exhibiting an increase of 2.5% compared to the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Fortive metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Sales- Intelligent Operating Solutions' should arrive at $668.90 million. The estimate points to a change of +5.4% from the year-ago quarter.
Analysts expect 'Sales- Advanced Healthcare Solutions' to come in at $353.19 million. The estimate indicates a year-over-year change of +3.2%.
Analysts predict that the 'Sales- Precision Technologies' will reach $546.46 million. The estimate points to a change of -1.2% from the year-ago quarter.
It is projected by analysts that the 'Adjusted Operating Profit (Non-GAAP)- Intelligent Operating Solutions' will reach $221.31 million. Compared to the current estimate, the company reported $198.10 million in the same quarter of the previous year.
The consensus estimate for 'Adjusted Operating Profit (Non-GAAP)- Advanced Healthcare Solutions' stands at $88.79 million. Compared to the present estimate, the company reported $82.60 million in the same quarter last year.
The average prediction of analysts places 'Adjusted Operating Profit (Non-GAAP)- Precision Technologies' at $151.11 million. Compared to the current estimate, the company reported $145.50 million in the same quarter of the previous year.
View all Key Company Metrics for Fortive here>>>
Over the past month, Fortive shares have recorded returns of +1% versus the Zacks S&P 500 composite's +3.1% change. Based on its Zacks Rank #2 (Buy), FTV will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216421/unveiling-fortive-ftv-q4-outlook-wall-street-estimates-for-key-metrics
| 2024-01-26T18:57:11Z
|
blocked_url
|
In its upcoming report, Roper Technologies (ROP - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $4.33 per share, reflecting an increase of 10.5% compared to the same period last year. Revenues are forecasted to be $1.58 billion, representing a year-over-year increase of 10.1%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Roper Technologies metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Revenue- Network Software & Systems' will reach $360.61 million. The estimate indicates a change of +2.9% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Application Software' should come in at $830.37 million. The estimate suggests a change of +12.2% year over year.
Analysts expect 'Operating Profit- Application Software' to come in at $223.71 million. The estimate is in contrast to the year-ago figure of $194.80 million.
The collective assessment of analysts points to an estimated 'Operating Profit- Network Software & Systems' of $157.73 million. The estimate is in contrast to the year-ago figure of $148.60 million.
View all Key Company Metrics for Roper Technologies here>>>
Over the past month, Roper Technologies shares have recorded returns of +1% versus the Zacks S&P 500 composite's +3.1% change. Based on its Zacks Rank #2 (Buy), ROP will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216422/unveiling-roper-technologies-rop-q4-outlook-wall-street-estimates-for-key-metrics
| 2024-01-26T18:57:17Z
|
blocked_url
|
Wall Street analysts expect Automatic Data Processing (ADP - Free Report) to post quarterly earnings of $2.10 per share in its upcoming report, which indicates a year-over-year increase of 7.1%. Revenues are expected to be $4.66 billion, up 6.1% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific ADP metrics that are commonly monitored and projected by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues- Interest on funds held for clients' should arrive at $228.85 million. The estimate points to a change of +22.3% from the year-ago quarter.
Analysts forecast 'Revenues- PEO revenues' to reach $1.54 billion. The estimate suggests a change of +2.2% year over year.
The combined assessment of analysts suggests that 'Revenues- Revenues, other than interest on funds held for clients and PEO revenues' will likely reach $2.90 billion. The estimate suggests a change of +7.2% year over year.
The average prediction of analysts places 'Segment revenues- Employer Services' at $3.11 billion. The estimate indicates a year-over-year change of +7.6%.
According to the collective judgment of analysts, 'Segment revenues- PEO Services' should come in at $1.55 billion. The estimate points to a change of +3.3% from the year-ago quarter.
The consensus estimate for 'Average paid PEO worksite employees during the period' stands at 726. Compared to the present estimate, the company reported 711 in the same quarter last year.
View all Key Company Metrics for ADP here>>>
Over the past month, shares of ADP have returned +1.8% versus the Zacks S&P 500 composite's +3.1% change. Currently, ADP carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216423/adp-adp-q2-earnings-on-the-horizon-analysts-insights-on-key-performance-measures
| 2024-01-26T18:57:19Z
|
blocked_url
|
The upcoming report from Meritage Homes (MTH - Free Report) is expected to reveal quarterly earnings of $5.18 per share, indicating a decline of 26.9% compared to the year-ago period. Analysts forecast revenues of $1.52 billion, representing a decrease of 23.5% year over year.
The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Meritage metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Revenue- Total closing revenue (Homebuilding)' will reach $1.52 billion. The estimate suggests a change of -23.6% year over year.
Analysts predict that the 'Revenue- Home closing' will reach $1.52 billion. The estimate points to a change of -23.6% from the year-ago quarter.
The consensus among analysts is that 'Revenue- Land closing' will reach $6.36 million. The estimate indicates a change of -13.3% from the prior-year quarter.
Analysts' assessment points toward 'Revenue- Financial Services' reaching $6.16 million. The estimate suggests a change of -16.3% year over year.
Based on the collective assessment of analysts, 'Homes ordered - Total' should arrive at 3,041. Compared to the present estimate, the company reported 1,808 in the same quarter last year.
The collective assessment of analysts points to an estimated 'Home Closing Revenue - Average sales price - Total' of $420.38. The estimate compares to the year-ago value of $437.
According to the collective judgment of analysts, 'Order Backlog - Total' should come in at 3,034. Compared to the present estimate, the company reported 3,332 in the same quarter last year.
Analysts forecast 'Homes closed - Total' to reach 3,608. The estimate compares to the year-ago value of 4,540.
Analysts expect 'Order Backlog - Average sales price - Total' to come in at $436.38. The estimate compares to the year-ago value of $458.
The consensus estimate for 'Order Backlog Value - Total' stands at $1.31 billion. Compared to the current estimate, the company reported $1.52 billion in the same quarter of the previous year.
The average prediction of analysts places 'Active Communities - Ending - Total' at 281. Compared to the present estimate, the company reported 271 in the same quarter last year.
The combined assessment of analysts suggests that 'Homes ordered - East Region' will likely reach 1,164. Compared to the current estimate, the company reported 732 in the same quarter of the previous year.
View all Key Company Metrics for Meritage here>>>
Shares of Meritage have experienced a change of -5.3% in the past month compared to the +3.1% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), MTH is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216424/wall-streets-insights-into-key-metrics-ahead-of-meritage-mth-q4-earnings
| 2024-01-26T18:57:25Z
|
blocked_url
|
The upcoming report from Rockwell Automation (ROK - Free Report) is expected to reveal quarterly earnings of $2.61 per share, indicating an increase of 6.1% compared to the year-ago period. Analysts forecast revenues of $2.07 billion, representing an increase of 4.5% year over year.
The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Rockwell Automation metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Sales- Intelligent Devices' should arrive at $989.42 million. The estimate suggests a change of +5.7% year over year.
The average prediction of analysts places 'Sales- Lifecycle Services' at $493.41 million. The estimate points to a change of +4.7% from the year-ago quarter.
Analysts' assessment points toward 'Sales- Software & Control' reaching $581.29 million. The estimate indicates a change of +1.4% from the prior-year quarter.
Analysts predict that the 'Operating earnings- Intelligent Devices' will reach $204.89 million. Compared to the current estimate, the company reported $209.40 million in the same quarter of the previous year.
According to the collective judgment of analysts, 'Operating earnings- Lifecycle Services' should come in at $33.33 million. Compared to the present estimate, the company reported $24.30 million in the same quarter last year.
Analysts expect 'Operating earnings- Software & Control' to come in at $172.41 million. The estimate compares to the year-ago value of $167.30 million.
View all Key Company Metrics for Rockwell Automation here>>>
Over the past month, Rockwell Automation shares have recorded returns of -2.1% versus the Zacks S&P 500 composite's +3.1% change. Based on its Zacks Rank #3 (Hold), ROK will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216425/ahead-of-rockwell-automation-rok-q1-earnings-get-ready-with-wall-street-estimates-for-key-metrics
| 2024-01-26T18:57:32Z
|
blocked_url
|
Wall Street analysts forecast that Thermo Fisher Scientific (TMO - Free Report) will report quarterly earnings of $5.64 per share in its upcoming release, pointing to a year-over-year increase of 4.4%. It is anticipated that revenues will amount to $10.74 billion, exhibiting a decline of 6.2% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Thermo Fisher metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus estimate for 'Revenues- Laboratory Products and Biopharma Services' stands at $5.83 billion. The estimate points to a change of -2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Specialty Diagnostics' will likely reach $1.11 billion. The estimate suggests a change of -0.7% year over year.
Analysts expect 'Revenues- Life Sciences Solutions' to come in at $2.40 billion. The estimate suggests a change of -21.2% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Analytical Instruments' of $1.87 billion. The estimate indicates a change of -0.3% from the prior-year quarter.
Based on the collective assessment of analysts, 'Operating Income- Life Sciences Solutions' should arrive at $767.62 million. The estimate compares to the year-ago value of $1.04 billion.
Analysts predict that the 'Operating Income- Laboratory Products and Biopharma Services' will reach $1.09 billion. The estimate compares to the year-ago value of $836 million.
Analysts forecast 'Operating Income- Specialty Diagnostics' to reach $231.74 million. The estimate is in contrast to the year-ago figure of $208 million.
The consensus among analysts is that 'Operating Income- Analytical Instruments' will reach $435.76 million. The estimate is in contrast to the year-ago figure of $476 million.
View all Key Company Metrics for Thermo Fisher here>>>
Shares of Thermo Fisher have experienced a change of +1% in the past month compared to the +3.1% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TMO is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216426/thermo-fisher-tmo-q4-earnings-preview-what-you-should-know-beyond-the-headline-estimates
| 2024-01-26T18:57:38Z
|
blocked_url
|
Analysts on Wall Street project that Qualcomm (QCOM - Free Report) will announce quarterly earnings of $2.38 per share in its forthcoming report, representing an increase of 0.4% year over year. Revenues are projected to reach $9.51 billion, increasing 0.5% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Qualcomm metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Revenue- QTL' should come in at $1.54 billion. The estimate indicates a change of +0.9% from the prior-year quarter.
It is projected by analysts that the 'Revenue- QCT' will reach $8.13 billion. The estimate indicates a year-over-year change of +3%.
Analysts forecast 'QCT revenues- Handsets' to reach $6.30 billion. The estimate suggests a change of +9.4% year over year.
The average prediction of analysts places 'QCT revenues- Automotive' at $518.99 million. The estimate points to a change of +13.8% from the year-ago quarter.
Based on the collective assessment of analysts, 'QCT revenues- IoT' should arrive at $1.28 billion. The estimate indicates a year-over-year change of -23.9%.
Analysts expect 'Revenues- Non-GAAP Reconciling Items' to come in at $31.68 million. The estimate indicates a change of -20.8% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Equipment and services' of $8.04 billion. The estimate indicates a change of +3.3% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Licensing' reaching $1.46 billion. The estimate indicates a year-over-year change of -13.2%.
The consensus among analysts is that 'Income / (loss) before taxes- QTL' will reach $1.01 billion. Compared to the current estimate, the company reported $1.12 billion in the same quarter of the previous year.
Analysts predict that the 'Income / (loss) before taxes- QCT' will reach $2.22 billion. The estimate compares to the year-ago value of $2.18 billion.
View all Key Company Metrics for Qualcomm here>>>
Over the past month, Qualcomm shares have recorded returns of +5.9% versus the Zacks S&P 500 composite's +3.1% change. Based on its Zacks Rank #3 (Hold), QCOM will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216427/insights-into-qualcomm-qcom-q1-wall-street-projections-for-key-metrics
| 2024-01-26T18:57:39Z
|
blocked_url
|
Analysts on Wall Street project that MetLife (MET - Free Report) will announce quarterly earnings of $1.95 per share in its forthcoming report, representing an increase of 25.8% year over year. Revenues are projected to reach $18.07 billion, increasing 14.1% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some MetLife metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Revenues- Premiums' will reach $11.23 billion. The estimate suggests a change of +20% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Other Revenues' of $633.77 million. The estimate points to a change of +0.9% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Universal life and investment-type product policy fees' will likely reach $1.34 billion. The estimate suggests a change of -1% year over year.
Analysts' assessment points toward 'Revenues- Net investment income' reaching $4.87 billion. The estimate suggests a change of +9.1% year over year.
Analysts forecast 'Revenue- Latin America- Total adjusted revenues' to reach $1.77 billion. The estimate indicates a change of +13.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- U.S. Business- Total adjusted revenues' should come in at $10.37 billion. The estimate suggests a change of +19.2% year over year.
Analysts predict that the 'Revenue- EMEA- Total adjusted revenues' will reach $661.26 million. The estimate points to a change of +9.7% from the year-ago quarter.
Analysts expect 'Revenue- Asia- Total adjusted revenues' to come in at $2.74 billion. The estimate indicates a year-over-year change of +5.6%.
The consensus estimate for 'Revenue- Corporate & other- Total adjusted revenues' stands at $220.70 million. The estimate points to a change of +50.1% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Asia- Net investment income' should arrive at $989.05 million. The estimate indicates a change of +19.5% from the prior-year quarter.
The average prediction of analysts places 'Revenue- EMEA- Net investment income' at $47.06 million. The estimate indicates a year-over-year change of +14.8%.
It is projected by analysts that the 'Revenue- Latin America- Net investment income' will reach $407.86 million. The estimate suggests a change of -1.2% year over year.
View all Key Company Metrics for MetLife here>>>
Shares of MetLife have experienced a change of +6.2% in the past month compared to the +3.1% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), MET is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216428/seeking-clues-to-metlife-met-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?-a-peek-into-wall-street-projections-for-key-metrics
| 2024-01-26T18:57:45Z
|
blocked_url
|
Analysts on Wall Street project that Corteva, Inc. (CTVA - Free Report) will announce quarterly earnings of $0.06 per share in its forthcoming report, representing a decline of 62.5% year over year. Revenues are projected to reach $3.54 billion, declining 7.4% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Corteva, Inc. metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Revenue- Seed' will reach $1.59 billion. The estimate suggests a change of -3.6% year over year.
Based on the collective assessment of analysts, 'Revenue- Crop Protection' should arrive at $1.93 billion. The estimate points to a change of -11.6% from the year-ago quarter.
Analysts' assessment points toward 'Operating EBITDA- Crop Protection' reaching $279.28 million. Compared to the current estimate, the company reported $332 million in the same quarter of the previous year.
View all Key Company Metrics for Corteva, Inc. here>>>
Corteva, Inc. shares have witnessed a change of -5.9% in the past month, in contrast to the Zacks S&P 500 composite's +3.1% move. With a Zacks Rank #3 (Hold), CTVA is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216429/unveiling-corteva-inc-ctva-q4-outlook-wall-street-estimates-for-key-metrics
| 2024-01-26T18:57:52Z
|
blocked_url
|
Analysts on Wall Street project that Novartis (NVS - Free Report) will announce quarterly earnings of $1.67 per share in its forthcoming report, representing an increase of 10.6% year over year. Revenues are projected to reach $11.69 billion, declining 7.9% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.3% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Novartis metrics that Wall Street analysts commonly model and monitor.
The consensus among analysts is that 'Revenues- Solid Tumors- Kisqali - Total' will reach $608.07 million. The estimate indicates a year-over-year change of +70.3%.
Based on the collective assessment of analysts, 'Revenues- Solid Tumors- Tafinlar + Mekinist - Total' should arrive at $502.28 million. The estimate points to a change of +8% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Neuroscience- Gilenya - Total' should come in at $231.53 million. The estimate points to a change of -33.1% from the year-ago quarter.
Analysts forecast 'Revenues- Immunology-Cosentyx - Total' to reach $1.34 billion. The estimate indicates a year-over-year change of +23.7%.
The combined assessment of analysts suggests that 'Revenues- Hematology- Tasigna - US' will likely reach $228.84 million. The estimate indicates a change of +2.6% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Hematology- Promacta/Revolade - US' reaching $263.34 million. The estimate points to a change of -6.6% from the year-ago quarter.
Analysts predict that the 'Revenues- Neuroscience- Gilenya - US' will reach $104.73 million. The estimate suggests a change of -44.6% year over year.
Analysts expect 'Revenues- Immunology- Cosentyx - US' to come in at $723.22 million. The estimate suggests a change of +14.3% year over year.
The consensus estimate for 'Revenues- Cardiovascular- Entresto - US' stands at $839.24 million. The estimate indicates a change of +20.9% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Hematology- Tasigna - Rest of the world' of $233.24 million. The estimate indicates a change of -7.5% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Solid Tumors- Tafinlar + Mekinist - Rest of the world' will reach $296.24 million. The estimate points to a change of +2.2% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Hematology- Promacta/Revolade - Rest of the world' at $256.79 million. The estimate suggests a change of -0.5% year over year.
View all Key Company Metrics for Novartis here>>>
Over the past month, shares of Novartis have returned +7% versus the Zacks S&P 500 composite's +3.1% change. Currently, NVS carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216430/novartis-nvs-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures
| 2024-01-26T18:57:58Z
|
blocked_url
|
Analysts on Wall Street project that Lennox International (LII - Free Report) will announce quarterly earnings of $3.46 per share in its forthcoming report, representing an increase of 31.6% year over year. Revenues are projected to reach $1.15 billion, increasing 4.8% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.5% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Lennox metrics that are commonly tracked and forecasted by Wall Street analysts.
The combined assessment of analysts suggests that 'Net Sales- Residential Heating & Cooling' will likely reach $746.56 million. The estimate indicates a change of +6.1% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Commercial Heating & Cooling' of $366.19 million. The estimate indicates a year-over-year change of +52.3%.
Analysts expect 'Segment Profit (loss)- Residential Heating & Cooling' to come in at $128.81 million. Compared to the current estimate, the company reported $119.20 million in the same quarter of the previous year.
Analysts' assessment points toward 'Segment Profit (loss)- Commercial Heating & Cooling' reaching $71.65 million. The estimate is in contrast to the year-ago figure of $27.90 million.
View all Key Company Metrics for Lennox here>>>
Shares of Lennox have experienced a change of -1.8% in the past month compared to the +3.1% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), LII is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216431/what-analyst-projections-for-key-metrics-reveal-about-lennox-lii-q4-earnings
| 2024-01-26T18:57:59Z
|
blocked_url
|
Analysts on Wall Street project that PTC Inc. (PTC - Free Report) will announce quarterly earnings of $0.98 per share in its forthcoming report, representing a decline of 1% year over year. Revenues are projected to reach $538.59 million, increasing 15.6% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone an upward revision of 4.9% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain PTC Inc. metrics that are commonly tracked and forecasted by Wall Street analysts.
The average prediction of analysts places 'Revenue- Recurring Revenue' at $494.70 million. The estimate indicates a change of +18.6% from the prior-year quarter.
The consensus estimate for 'Revenue- Professional Services' stands at $32.97 million. The estimate indicates a year-over-year change of -7.3%.
The collective assessment of analysts points to an estimated 'Revenue- Total Software (License+Support & cloud services)' of $503.93 million. The estimate suggests a change of +17.1% year over year.
Analysts' assessment points toward 'Revenue- Perpetual License' reaching $9.24 million. The estimate points to a change of -30.3% from the year-ago quarter.
Analysts predict that the 'ARR by Product Group - Total' will reach $2.00 billion. The estimate compares to the year-ago value of $1.66 billion.
View all Key Company Metrics for PTC Inc. here>>>
Over the past month, PTC Inc. shares have recorded returns of +2.3% versus the Zacks S&P 500 composite's +3.1% change. Based on its Zacks Rank #2 (Buy), PTC will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216432/gear-up-for-ptc-inc-ptc-q1-earnings-wall-street-estimates-for-key-metrics
| 2024-01-26T18:58:06Z
|
blocked_url
|
Wall Street analysts expect Boeing (BA - Free Report) to post quarterly loss of $0.72 per share in its upcoming report, which indicates a year-over-year increase of 58.9%. Revenues are expected to be $21.23 billion, up 6.2% from the year-ago quarter.
The current level reflects an upward revision of 4.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Boeing metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Total revenues- Global Services' will reach $4.79 billion. The estimate points to a change of +4.8% from the year-ago quarter.
Analysts' assessment points toward 'Total Revenues- Defense, Space & Security' reaching $6.27 billion. The estimate indicates a year-over-year change of +1.4%.
The average prediction of analysts places 'Total Revenues- Commercial Airplanes' at $10.23 billion. The estimate suggests a change of +10.9% year over year.
Analysts forecast 'Deliveries - Total' to reach 156. The estimate compares to the year-ago value of 152.
The collective assessment of analysts points to an estimated 'Deliveries - Commercial Airplanes - 737' of 110. Compared to the current estimate, the company reported 110 in the same quarter of the previous year.
The combined assessment of analysts suggests that 'Deliveries - Commercial Airplanes - 787' will likely reach 23. The estimate is in contrast to the year-ago figure of 22.
Based on the collective assessment of analysts, 'Deliveries - Commercial Airplanes - 777' should arrive at 9. Compared to the present estimate, the company reported 6 in the same quarter last year.
The consensus estimate for 'Deliveries - Commercial Airplanes - 767' stands at 14. The estimate compares to the year-ago value of 12.
The consensus among analysts is that 'Earnings/(loss) from operations- Global Services' will reach $841.30 million. The estimate compares to the year-ago value of $634 million.
View all Key Company Metrics for Boeing here>>>
Over the past month, shares of Boeing have returned -22.5% versus the Zacks S&P 500 composite's +3.1% change. Currently, BA carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216433/boeing-ba-q4-earnings-preview-what-you-should-know-beyond-the-headline-estimates
| 2024-01-26T18:58:12Z
|
blocked_url
|
Wall Street analysts expect Aptiv PLC (APTV - Free Report) to post quarterly earnings of $1.27 per share in its upcoming report, which indicates no change from the year-ago quarter. Revenues are expected to be $4.93 billion, up 6.2% from the year-ago quarter.
The current level reflects a downward revision of 0.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Aptiv PLC metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Net Sales- Signal and Power Solutions' to come in at $3.53 billion. The estimate points to a change of +4.7% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- Advanced Safety and User Experience' will reach $1.38 billion. The estimate indicates a year-over-year change of +8.2%.
The average prediction of analysts places 'Adjusted Operating Income- Advanced Safety and User Experience' at $128.86 million. Compared to the current estimate, the company reported $77 million in the same quarter of the previous year.
It is projected by analysts that the 'Adjusted Operating Income- Signal and Power Solutions' will reach $462.57 million. The estimate compares to the year-ago value of $446 million.
View all Key Company Metrics for Aptiv PLC here>>>
Aptiv PLC shares have witnessed a change of -6.6% in the past month, in contrast to the Zacks S&P 500 composite's +3.1% move. With a Zacks Rank #4 (Sell), APTV is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216434/insights-into-aptiv-plc-aptv-q4-wall-street-projections-for-key-metrics
| 2024-01-26T18:58:18Z
|
blocked_url
|
Wall Street analysts expect Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) to post quarterly earnings of $0.75 per share in its upcoming report, which indicates a year-over-year increase of 5.6%. Revenues are expected to be $3.96 billion, up 2% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Teva Pharmaceutical Industries Ltd. metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenue- Other- Total' at $194.26 million. The estimate points to a change of -16.3% from the year-ago quarter.
Analysts expect 'Revenue- API sales to third parties' to come in at $159.44 million. The estimate suggests a change of -5.1% year over year.
It is projected by analysts that the 'Revenue- COPAXONE- Total' will reach $139.08 million. The estimate indicates a change of -17.7% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenue- International Markets' reaching $473.55 million. The estimate indicates a change of -1.8% from the prior-year quarter.
According to the collective judgment of analysts, 'Geographic Revenue- North America' should come in at $2.04 billion. The estimate indicates a year-over-year change of +1.8%.
The consensus among analysts is that 'Geographic Revenue- North America- COPAXONE' will reach $75.07 million. The estimate indicates a year-over-year change of -25.7%.
Analysts forecast 'Geographic Revenue- North America- BENDEKA / TREANDA' to reach $49.38 million. The estimate indicates a change of -34.2% from the prior-year quarter.
The consensus estimate for 'Geographic Revenue- North America- AUSTEDO' stands at $422.38 million. The estimate indicates a change of +22.8% from the prior-year quarter.
Analysts predict that the 'Geographic Revenue- North America- Anda' will reach $450.39 million. The estimate indicates a year-over-year change of +0.1%.
The combined assessment of analysts suggests that 'Geographic Revenue- Europe- COPAXONE' will likely reach $45.16 million. The estimate indicates a year-over-year change of -26%.
Based on the collective assessment of analysts, 'Geographic Revenue- Europe- Respiratory products' should arrive at $71.77 million. The estimate indicates a year-over-year change of -4.3%.
The collective assessment of analysts points to an estimated 'Geographic Revenue- International Markets- Generic products' of $403.85 million. The estimate indicates a year-over-year change of -1.7%.
View all Key Company Metrics for Teva Pharmaceutical Industries Ltd. here>>>
Shares of Teva Pharmaceutical Industries Ltd. have experienced a change of +13% in the past month compared to the +3.1% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TEVA is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216435/unveiling-teva-pharmaceutical-industries-ltd-teva-q4-outlook-wall-street-estimates-for-key-metrics
| 2024-01-26T18:58:20Z
|
blocked_url
|
Analysts on Wall Street project that Align Technology (ALGN - Free Report) will announce quarterly earnings of $2.17 per share in its forthcoming report, representing an increase of 25.4% year over year. Revenues are projected to reach $928.43 million, increasing 3% from the same quarter last year.
Over the last 30 days, there has been an upward revision of 1.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Align Technology metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Net revenues- Total Clear Aligner' should come in at $753.00 million. The estimate points to a change of +2.9% from the year-ago quarter.
Analysts forecast 'Net revenues- Imaging Systems and CAD/CAM Services' to reach $175.81 million. The estimate indicates a year-over-year change of +3.5%.
Analysts predict that the 'Clear Aligner Shipments' will reach 592. The estimate compares to the year-ago value of 584.
View all Key Company Metrics for Align Technology here>>>
Over the past month, shares of Align Technology have returned -5.3% versus the Zacks S&P 500 composite's +3.1% change. Currently, ALGN carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216436/gear-up-for-align-technology-algn-q4-earnings-wall-street-estimates-for-key-metrics
| 2024-01-26T18:58:26Z
|
blocked_url
|
Analysts on Wall Street project that AvalonBay Communities (AVB - Free Report) will announce quarterly earnings of $2.73 per share in its forthcoming report, representing an increase of 5.4% year over year. Revenues are projected to reach $701.67 million, increasing 4.8% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain AvalonBay metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus estimate for 'Revenue- Rental and other income' stands at $700.50 million. The estimate indicates a change of +5.1% from the prior-year quarter.
Analysts predict that the 'Revenue- Management, development and other fees' will reach $1.87 million. The estimate indicates a year-over-year change of -42.9%.
Based on the collective assessment of analysts, 'Depreciation expense' should arrive at $204.52 million. Compared to the current estimate, the company reported $207.23 million in the same quarter of the previous year.
View all Key Company Metrics for AvalonBay here>>>
Over the past month, AvalonBay shares have recorded returns of -7.1% versus the Zacks S&P 500 composite's +3.1% change. Based on its Zacks Rank #3 (Hold), AVB will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216437/wall-streets-insights-into-key-metrics-ahead-of-avalonbay-avb-q4-earnings
| 2024-01-26T18:58:32Z
|
blocked_url
|
Analysts on Wall Street project that MasterCard (MA - Free Report) will announce quarterly earnings of $3.08 per share in its forthcoming report, representing an increase of 16.2% year over year. Revenues are projected to reach $6.46 billion, increasing 11% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain MasterCard metrics that are commonly tracked and forecasted by Wall Street analysts.
According to the collective judgment of analysts, 'Switched transactions' should come in at 37,553.45 million. Compared to the present estimate, the company reported 33,959 million in the same quarter last year.
The combined assessment of analysts suggests that 'Gross dollar volume - All Mastercard Credit, Charge and Debit Programs - Latin America' will likely reach $197.40 billion. The estimate compares to the year-ago value of $169 billion.
Analysts expect 'Gross dollar volume - All Mastercard Credit, Charge and Debit Programs - Europe' to come in at $767.88 billion. Compared to the current estimate, the company reported $648 billion in the same quarter of the previous year.
It is projected by analysts that the 'Gross dollar volume - All Mastercard Credit, Charge and Debit Programs - Canada' will reach $69.77 billion. The estimate is in contrast to the year-ago figure of $63 billion.
Analysts predict that the 'Gross dollar volume - All Mastercard Credit, Charge and Debit Programs - APMEA' will reach $594.36 billion. The estimate compares to the year-ago value of $554 billion.
The collective assessment of analysts points to an estimated 'Gross dollar volume - All Mastercard Credit, Charge and Debit Programs - Worldwide less United States' of $1,629.41 billion. Compared to the current estimate, the company reported $1,434 billion in the same quarter of the previous year.
Analysts forecast 'Gross dollar volume - All Mastercard Credit, Charge and Debit Programs - United States' to reach $738.70 billion. The estimate is in contrast to the year-ago figure of $699 billion.
Analysts' assessment points toward 'Gross dollar volume - All Mastercard Credit, Charge and Debit Programs - Worldwide' reaching $2,368.11 billion. The estimate compares to the year-ago value of $2,133 billion.
The average prediction of analysts places 'Gross dollar volume - All MasterCard Debit Programs - Worldwide' at $1,199.01 billion. The estimate compares to the year-ago value of $1,120 billion.
The consensus among analysts is that 'Gross dollar volume - All MasterCard Debit Programs - Worldwide less United States' will reach $851.10 billion. Compared to the present estimate, the company reported $784 billion in the same quarter last year.
Based on the collective assessment of analysts, 'Gross dollar volume - All MasterCard Debit Programs - United States' should arrive at $347.92 billion. The estimate is in contrast to the year-ago figure of $336 billion.
The consensus estimate for 'Gross dollar volume - All MasterCard Credit and Charge Programs - Worldwide' stands at $1,155.97 billion. The estimate is in contrast to the year-ago figure of $1,013 billion.
View all Key Company Metrics for MasterCard here>>>
Over the past month, shares of MasterCard have returned +2.5% versus the Zacks S&P 500 composite's +3.1% change. Currently, MA carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216438/exploring-analyst-estimates-for-mastercard-ma-q4-earnings-beyond-revenue-and-eps
| 2024-01-26T18:58:38Z
|
blocked_url
|
Have you been paying attention to shares of Lam Research (LRCX - Free Report) ? Shares have been on the move with the stock up 9.6% over the past month. The stock hit a new 52-week high of $900.09 in the previous session. Lam Research has gained 10.5% since the start of the year compared to the 63.7% move for the Zacks Computer and Technology sector and the 71.5% return for the Zacks Semiconductor Equipment - Wafer Fabrication industry.
What's Driving the Outperformance?
The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on January 24, 2024, Lam Research reported EPS of $7.52 versus consensus estimate of $7.06.
For the current fiscal year, Lam Research is expected to post earnings of $28.03 per share on $14.66 billion in revenues. This represents a -17.97% change in EPS on a -15.88% change in revenues. For the next fiscal year, the company is expected to earn $33.43 per share on $16.68 billion in revenues. This represents a year-over-year change of 19.29% and 13.8%, respectively.
Valuation Metrics
Lam Research may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Lam Research has a Value Score of D. The stock's Growth and Momentum Scores are B and A, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 30.9X current fiscal year EPS estimates, which is a premium to the peer industry average of 26.9X. On a trailing cash flow basis, the stock currently trades at 23.3X versus its peer group's average of 21.6X. Additionally, the stock has a PEG ratio of 11.44. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Lam Research currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Lam Research passes the test. Thus, it seems as though Lam Research shares could still be poised for more gains ahead.
|
https://www.zacks.com/stock/news/2216439/lam-research-corporation-lrcx-hits-fresh-high-is-there-still-room-to-run?
| 2024-01-26T18:58:40Z
|
blocked_url
|
Shares of HealthEquity (HQY - Free Report) have been strong performers lately, with the stock up 16.6% over the past month. The stock hit a new 52-week high of $78.26 in the previous session. HealthEquity has gained 16.6% since the start of the year compared to the -1.4% move for the Zacks Medical sector and the -5.2% return for the Zacks Medical Services industry.
What's Driving the Outperformance?
The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on December 5, 2023, HealthEquity reported EPS of $0.6 versus consensus estimate of $0.49 while it beat the consensus revenue estimate by 2.29%.
For the current fiscal year, HealthEquity is expected to post earnings of $2.15 per share on $992.94 million in revenues. This represents a 58.09% change in EPS on a 15.22% change in revenues. For the next fiscal year, the company is expected to earn $2.79 per share on $1.15 billion in revenues. This represents a year-over-year change of 29.77% and 15.74%, respectively.
Valuation Metrics
HealthEquity may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
HealthEquity has a Value Score of C. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 36X current fiscal year EPS estimates, which is a premium to the peer industry average of 19.9X. On a trailing cash flow basis, the stock currently trades at 28.5X versus its peer group's average of 8.7X. Additionally, the stock has a PEG ratio of 1.26. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, HealthEquity currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if HealthEquity meets the list of requirements. Thus, it seems as though HealthEquity shares could have a bit more room to run in the near term.
How Does HQY Stack Up to the Competition?
Shares of HQY have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Elevance Health, Inc. (ELV - Free Report) . ELV has a Zacks Rank of # 2 (Buy) and a Value Score of A, a Growth Score of A, and a Momentum Score of A.
Earnings were strong last quarter. Elevance Health, Inc. beat our consensus estimate by 1.26%, and for the current fiscal year, ELV is expected to post earnings of $37.05 per share on revenue of $173.61 billion.
Shares of Elevance Health, Inc. have gained 2.5% over the past month, and currently trade at a forward P/E of 12.97X and a P/CF of 13.2X.
The Medical Services industry may rank in the bottom 72% of all the industries we have in our universe, but there still looks like there are some nice tailwinds for HQY and ELV, even beyond their own solid fundamental situation.
|
https://www.zacks.com/stock/news/2216440/healthequity-inc-hqy-hit-a-52-week-high-can-the-run-continue?
| 2024-01-26T18:58:47Z
|
blocked_url
|
First Hawaiian (FHB - Free Report) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -17.78%. A quarter ago, it was expected that this bank holding company would post earnings of $0.44 per share when it actually produced earnings of $0.46, delivering a surprise of 4.55%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
First Hawaiian
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
First Hawaiian shares have lost about 5.5% since the beginning of the year versus the S&P 500's gain of 2.6%.
What's Next for First Hawaiian?
While First Hawaiian has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for First Hawaiian: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.42 on $200.07 million in revenues for the coming quarter and $1.73 on $809.47 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - West is currently in the bottom 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Central Pacific Financial (CPF - Free Report) , has yet to report results for the quarter ended December 2023. The results are expected to be released on January 31.
This operator of Central Pacific Bank is expected to post quarterly earnings of $0.48 per share in its upcoming report, which represents a year-over-year change of -35.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Central Pacific Financial's revenues are expected to be $61.18 million, down 9.9% from the year-ago quarter.
|
https://www.zacks.com/stock/news/2216441/first-hawaiian-fhb-q4-earnings-lag-estimates
| 2024-01-26T18:58:53Z
|
blocked_url
|
Jada Pinkett Smith revealed that there's one topic which has all members of her family divided, as she opened up on the Off Menu podcast.
The actress talked about all things food and family on the podcast hosted by British comedians Ed Gamble and James Acaster, who talk famous guests through their dream meal from starter to dessert. But as Jada opened up about what she likes to eat, she made some interesting revelations about life in the Pinkett Smith household along the way.
Jada explained that she is not really a foodie - but Willow and Will are.
"My daughter is a hardcore foodie, and so is Will. Hardcore foodies, so I've had to learn how to enjoy meals", she revealed.
When asked if her son Jaden was a foodie, the mom revealed that "Jaden's not really… He's not really a foodie. And I'd have to say my bonus son Trey is probably in between."
James pointed out that perhaps Jaden might have to join Jada on her journey to becoming a foodie, but the hosts agreed that the family seems to cover a whole range of different relationships to food. But Jada explained that her "interesting" relationship with food came from her grandmother.
"My grandmother probably was the only West Indian that I know that can't cook", she laughed, "So she would make stuff like cow tongue with cream cheese in the crock pot."
Jada's grandmother instilled in her that "food is not meant to be enjoyed, it is for nutrition", which might explain why she doesn't consider herself to be a foodie like her daughter and husband.
As well as revealing that the family are split on the topic of eating, Jada explained how magician David Blaine "showed the connection between" her and Will.
"He touched Will's shoulder, and I felt it but Will didn't." Jada explained, adding that she cried because "it was emotional. I was like 'no way! How did you do that?'"
The Madagascar actress had her eyes closed during the trick, and as the magician touched Will's shoulder, she felt the sensation where her husband didn't.
"He was like showing the connection between us", she said, before joking, "and I haven't been able to get away from Will since because of that connection!"
"I blame it on David! We are really connected!" she chuckled.
Her connection with her husband was arguably put to the test as she revealed back in October that she and her husband had been separated for seven years, although remained legally married, and were working on rekindling their connection.
Speaking to Fearne Cotton about what she saw in her husband, Jada revealed that: "He is all sky, happy. He's looking at the glass as half full and I'm looking at it half empty. Even to this day…he's just always looking for a laugh."
|
https://www.hellomagazine.com/celebrities/512145/jada-pinkett-smith-will-smith-family-divided-reveals-kids-willow-jaden-trey-eating-habits/
| 2024-01-26T18:58:59Z
|
blocked_url
|
Alphabet’s (GOOGL - Free Report) is leaving no stone unturned to bolster its product offerings on the back of its growing generative AI capabilities.
In this regard, the company recently added generative AI features, namely “Tab Organizer” and a theme maker, to Chrome 121.
Notably, the Tab Organizer feature automatically creates tab groups based on open tabs by tapping the downward-facing icon in the top-left corner on Windows or right in macOS.
Further, the feature provides a Tab Group suggestion with a name and emoji, which users must manually accept and can be rated up or down.
Additionally, Chrome now allows users to create custom themes for the New Tab Page using a generative AI text-to-image diffusion model, offering six suggested options and recent creations.
These new generative AI feature additions are expected to boost traffic on the Chrome browser. This, in turn, is expected to bolster the Google Services segment, which has been the key growth catalyst for Alphabet.
Expanding Generative AI-Backed Offering
Apart from the latest generative AI additions to Chrome, Google's Art Selfie 2 uses generative AI to match users' faces with existing artworks, allowing them to find doppelgangers.
Further, Art Selfie 2 uses generative AI to create a stylized image of users’ faces, blending your selfie into a chosen scenario, allowing hair, head coverings, jewelry and clothing to be replaced.
Alphabet also introduced an AI support assistant, which allows users to expand and ask questions, with the option to leave a thumb-up or down, view answer sources and suggest follow-up questions, enhancing its generative AI capabilities for virtual assistance.
The company is also set to introduce a generative AI-powered “Help me write” feature to Chrome for Desktop use. This new AI feature can adjust its writing style, including "Shorten" or "Elaborate" options, as well as "Casual" or "Formal" options, with fewer options than Docs or Messages.
The company’s growing endeavors to infuse generative AI capabilities into its product offerings will result in an enhanced user experience, allowing Alphabet to capitalize on the growth opportunities in the generative AI market space.
Per an Allied Market Research report, the global generative AI market is expected to reach $191.8 billion by 2032, witnessing a CAGR of 34.1% between 2023 and 2032.
Solidifying prospects in the promising gen AI market is expected to benefit Alphabet’s overall financial performance in the near term.
Intensifying Competition
The latest move is likely to aid Alphabet in strengthening its competitive position against peers like Microsoft (MSFT - Free Report) , Amazon (AMZN - Free Report) and Meta Platforms (META - Free Report) , which are also making continuous efforts to capitalize on the growth opportunities present in the booming generative AI market.
Notably, Microsoft’s OpenAI introduced the GPT Store to create a marketplace for specialized chatbot agents based on their language models, particularly ChatGPT, allowing users to create unique agents for various purposes like salary negotiation and recipe development.
Further, Microsoft plans to offer users the ability to customize Copilot, a generative AI assistant, with customized versions called Copilot GPTs. These GPTs will be tailored for specific purposes like fitness, travel, or business.
Meanwhile, Amazon announced generative AI capabilities for its virtual assistant Alexa, optimizing voice interactions, real-time information, smart home control and entertainment.
Amazon also unveiled Titan Image Generator, a generative AI model that can create new or customize existing images, currently available in preview on Bedrock's AI development platform. This image generator tool uses English natural language prompts to create realistic images for advertising, e-commerce and media.
Meta, on the other hand, unveiled Meta AI, an advanced conversational assistant for WhatsApp, Messenger, Instagram, Ray-Ban Meta smart glasses and Quest 3, providing real-time information and photorealistic images.
Meta AI uses Meta’s state-of-the-art foundational language model, Llama 2, for text-based chats, accessing real-time information through Bing's search partnership and offering image generation tools.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Amazon.com, Inc. (AMZN) - free report >>
Microsoft Corporation (MSFT) - free report >>
|
https://www.zacks.com/stock/news/2216442/alphabet-googl-adds-generative-ai-capabilities-to-chrome
| 2024-01-26T18:59:00Z
|
blocked_url
|
Quest Diagnostics' (DGX - Free Report) wholly-owned subsidiary Haystack Oncology recently formed a research collaboration with TriSalus Life Sciences. Per the deal, Haystack Oncology, the developer of Haystack MRD, a best-in-class personalized minimal residual disease (MRD) technology, plans to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.
This research collaboration holds the promise of significantly advancing DGX’s Haystack Oncology’s research portfolio.
More on the News
TriSalus' SD-101 holds potential for patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma and pancreatic adenocarcinoma. The collaboration leverages Quest Diagnostics’ Haystack MRD, a cutting-edge personalized MRD technology designed to detect circulating tumor DNA (ctDNA) with unparalleled sensitivity. This facilitates accurate measurement of molecular response and early evidence of treatment efficacy, crucial elements in the complex landscape of cancer treatment.
Strategic Significance
Liver and pancreatic tumors pose unique challenges, especially in the early measurement of response treatment. Conventional imaging methods may fall short, making accurate ctDNA assays indispensable. Steven Katz, MD, chief medical officer of TriSalus Life Sciences, highlights the significance of accurate ctDNA assays in identifying meaningful biologic activity in these challenging-to-treat cancers.
Hepatocellular carcinoma, intrahepatic cholangiocarcinoma and pancreatic adenocarcinoma are aggressive forms of cancer. By combining Haystack Oncology's expertise in detecting minimal residual disease with TriSalus' innovative therapy delivery technology, this collaboration aims to pave the way for improved therapeutic options for these cancers.
Market Prospects and Other Stocks in This Space
The cancer diagnostics segment holds immense potential and is projected to rise at a CAGR of 8.8% through 2032. Continuous product development, growing demand for early cancer diagnosis and advanced laboratory equipment will propel growth in the healthcare and diagnostics sector.
Molecular diagnostics company, Exact Sciences’ (EXAS - Free Report) , flagship Cologuard screening test and Oncotype DX are fueling a nearly $2.5 billion business, having generated more than one million test results in the third quarter of 2023. Cologuard has presumably detected pre-cancerous polyps and early-stage cancer in nearly half a million people in the past 10 years. There is still a lot of scope, given that Cologuard’s market penetration is only 10% among an average of 60 million Americans who are not up-to-date with their screening.
Exact Sciences targets to raise the performance bar high in non-invasive screening with what it calls Cologuard 2.0 or the next-generation Cologuard. In precision oncology, Exact Sciences secured reimbursement for the Oncotype DX Breast test in Japan, its potential major market outside the United States.
Global life sciences company, Labcorp (LH - Free Report) is making targeted R&D investments in oncology, one of its primary growth areas. In 2023, the company forged a partnership with ImmunoGen on an immunohistochemistry-sponsored testing program to increase access for patients with ovarian cancer. Labcorp added HER2 low reporting to the IC test, which is the only FDA-approved companion diagnostic of HER2 status for patients with metastatic breast cancer.
Further, LabCorp’s portfolio of kits and solutions from the acquisition of PGDx is gaining momentum with major health systems and academic centers and aiding hospitals and health systems to execute their precision medicine programs.
As a leader in genetic testing and precision medicine, Myriad Genetics (MYGN - Free Report) has been gaining share in the hereditary cancer market driven by competitive account wins and increased adoption by providers of myRisk. The company continues to see momentum in its prenatal business as well.
Myriad Genetics is also well-poised to capitalize on the vast potential of the breast cancer screening market. Per a report by Grand View Research on Medium, the breast cancer screening market in the United States is expected to reach a value of roughly $6.8 billion by 2028.
The company entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of MRD testing in breast cancer. The research project will use Myriad Genetics' MRD testing platform. This tumor-informed high-definition assay uses whole-genome sequencing to achieve high sensitivity and specificity for ctDNA. Myriad Genetics' MRD test was selected for its anticipated higher sensitivity and specificity over other ctDNA offerings.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Quest Diagnostics Incorporated (DGX) - free report >>
|
https://www.zacks.com/stock/news/2216443/quest-diagnostics-dgx-advances-in-cancer-research-with-new-deal
| 2024-01-26T18:59:00Z
|
blocked_url
|
Tim McGraw has always made it clear that he is incredibly proud of his three daughters, all grown up, that he shares with wife Faith Hill.
The country star made sure there was little doubt of this as he enthused about his three daughters' incredible talent on Instagram, as he responded to a video posted by his youngest, Audrey.
The video posted by the 22-year-old saw her belting out 'Stand By Your Man' by country legend Tammy Wynette. Having clearly inherited her parents' incredible talent, Audrey powerfully performed the song as a piano ballad and sang her heart out.
Tim responded to his daughter's incredible talent by sharing his reaction alongside on his own Instagram, watching his daughter with glistening eyes as he was clearly moved by her voice.
He captioned the video: "We love it when @audreymcgraw comes home and sits at the piano…. She’s a true artist and we love the things she’s writing too!"
He said in the adorable video: "Our baby girl Audrey. Gosh, she's so talented, man. I've said it a hundred times, all of our girls are so talented. They all sing great."
He continued about his youngest daughter: "Audrey, she's just so special. She's such an incredible writer as well. I mean, we get to hear this whenever she's home, she'll sit on the piano. We can hear this all through the house."
"We can hear the stuff that she's writing", he revealed. "And I'm telling you, her voice and the things that she writes are just so mind blowing and deep and so special. She's a true artist with a true artist's soul."
The 'It's Your Love' singer revealed that sometimes he and his wife "will just sit there and listen."
"She doesn't know that we're listening half the time, sometimes we have to sneak around so we can watch her so she doesn't see us because she'll stop sometimes. But my goodness I am proud."
Visibly affected by his love for his daughters, Tim sniffled slightly - emotional about the level of talent they clearly have. "Wow. Gosh, these girls", he said.
This isn't the first time that Tim has gushed over his daughter's talents, as his wife and daughters were filmed singing as a family in an incredible clip.
He joked: "I'm the worst singer in the family. It's true. I'm pretty good, but I'm the worst singer in the family."
But can we expect a family performance any time soon?
"Maybe I'll talk them into it," he told ET. "Maybe they'll sort of grow out of that phase a little bit where they don't want to sing with me. They'll sing with Mom, but I'm probably not up to par with the rest of them."
|
https://www.hellomagazine.com/celebrities/512162/tim-mcgraw-emotional-gushes-talented-daughters-faith-hill-adorable-video/
| 2024-01-26T18:59:05Z
|
blocked_url
|
Archer Aviation Inc. (ACHR - Free Report) recently announced that it has signed a Space Act Agreement with the National Aeronautics and Space Administration (“NASA”) to promote mission-critical electric vertical takeoff and landing (eVTOL) aircraft technologies in the United States. As part of the joint effort, the two organizations will study high-performance batteries for Advanced Air Mobility (AAM) and space applications.
NASA will test the battery design developed for the Archer Midnight eVTOL aircraft. Under the collaboration, NASA and Archer will examine the battery’s safety, energy and performance using advanced X-ray facilities. The partnership will also ensure the mass production and adoption of electric aviation.
Archer’s Take in eVTOL
Archer’s eVTOL aircraft, Midnight, is a piloted, four-passenger aircraft powered by six independent battery packs. The aircraft is capable of flying around 20-mile back-to-back trips, with around 12-minute charging sessions in between.
It is considered to be a safe, low-cost and low-noise vehicle for air travel.
Prospects in the AAM Market
With the woes of the pandemic behind us and economies across the globe witnessing growth once again, the AAM industry is experiencing an upward trajectory. The increased investments and government regulations in support of the industry are driving the demand for AAM globally. To this end, per a report by The Insight Partners firm, the AAM market is estimated to reach $12,730.44 million by 2030.
Such solid market growth prospects should aid Archer Aviation, a prominent AAM player in the world. Archer aims to deliver a high-performing battery pack with leading safety features for its Midnight electric air taxi. These cells are tailor-made for aerospace applications, including eVTOL, electric conventional takeoff and landing (eCTOL) aircraft and potential usage in space.
As the NASA’s testing progresses, favorable results should boost the demand for Midnight aircraft, contributing to ACHR’s broader advancements in the AAM market.
Opportunities for Peers
Other aircraft manufacturers that may gain from the flourishing market prospects are as follows:
Boeing (BA - Free Report) : Wisk, a fully-owned subsidiary of Boeing, is one of the only AAM companies to pursue a self-flying first approach. Jointly with Boeing, it has developed a Concept of Operations for uncrewed passenger-carrying urban air mobility.
The Generation 6 aircraft is the world’s first all-electric, autonomous, four-seat air taxi designed for passenger transport. It has an operational range of 144 km and a cruising speed of 110-120 knots.
Airbus (EADSY - Free Report) : Airbus Urban Mobility oversees the development of eVTOLs. The company has successfully developed two electric VTOL demonstrators, CityAirbus and Vahana.
Airbus’ new generation eVTOL, the CityAirbus NextGen is a fully integrated, four-seat eVTOL vehicle. With an operational range of 80 km and a cruise speed of 120 km/h, it is a safe and reliable air mobility service.
Textron (TXT - Free Report) : Bell, a subsidiary of Textron, has developed high-speed vertical lift technology for more than 85 years. The company is leveraging its extensive investment in High-Speed Vertical Takeoff and Landing technology to demonstrate advanced performance capabilities. The portfolio includes VTOL configurations like the X-14, X-22, XV-3 and XV-15.
The Bell Autonomous Pod Transport has an operational range of 56 km and a cruising speed of 70 m/h. With high speed and quieter flight, the vehicle provides military, medical and logistical support.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
The Boeing Company (BA) - free report >>
Textron Inc. (TXT) - free report >>
|
https://www.zacks.com/stock/news/2216444/archer-achr-partners-nasa-to-study-evtol-technologies
| 2024-01-26T18:59:06Z
|
blocked_url
|
With the rising popularity of comfortable shoes post-pandemic and the runway's penchant for preppy style, it should come as no surprise the loafer is undoubtedly the shoe of the moment.
Practical and super cool, the style once reserved mostly for workwear is now a mainstay on the fashion circuit and suitable for everything from the office to date night.
Prada cemented the chunky loafer's place among the street style set with the launch of the Monolith, but for those who don’t favour a lug sole, you might find a classic pair of penny loafers more wearable, particularly for every day. First made popular in the 1950s, they’re categorised by their moccasin, slip-on style and horizontal strap (or saddle) across the instep.
Whether you’re looking for a sleek pair Gucci-style or a Prada-esque chunky pair, scroll on for the best loafers for women to shop now.
The best loafers for women at a glance
The Gucci loafers: Gucci Brixton Loafers, £675 / $920
The Prada loafers: Prada Monolith Loafers, £830 / $1,270
The penny loafers: & Other Stories Leather Penny Loafers, £120 / $149
The chunky loafers: Grenson Hattie Loafers, £380 / $515
Loafers have long been a favourite of Hailey Bieber who has proven their versatility by styling them with wide-leg trousers, mini skirts and blazer dresses. She loves her Eytys and Prada loafers and even has a pair from high street brand Vagabond.
Loafers are also synonymous with Sienna Miller who has been wearing them for years. She most often styles them with off-duty denim and has the Gucci Brixon loafers in both black and red. We'd love to raid her shoe collection, which includes a classic black pair by Khaite and a white slip-on style from Tory Burch.
Most recently we spotted Elsa Hosk in a pair of black quilted Chanel loafers and a tailored linen two-piece from her own fashion line. The supermodel has previously stepped out in a chunky pair, adding edge to an all-white trouser suit.
How we chose the best loafers for women
Variety: Both chunky loafers and sleeker styles are very much on trend so our edit includes a mix of the two.
Price: From designer to high street, we've found the most coveted loafers worn by celebrities as well as affordable pairs that cost less than £25.
Appropriate for the office: Keeping comfort and versatility in mind, many of these loafers are practical enough to wear to work.
Prada Loafers
Prada Monolith Loafers
Sizes available: UK 5-12
Colours available: Black
Shipping: Free Standard Delivery for orders over £400
Returns: Free within 14 days
Hitting the sweet spot of both cool and comfortable, it’s no wonder Prada’s now Monolith loafers are so popular. Made from real leather with a chunky rubber sole, they're also decorated with the brand's enamelled metal triangle logo. Style them with a mini skirt, ankle socks and an oversized blazer for the classic It-girl look.
Gucci Loafers
Gucci Brixton Loafers
Sizes available: EUR 34-42
Colours available: Black, Red
Shipping: £7 Standard Delivery or free for orders over £300
Returns: Free within 30 days
Investing in a forever pair to wear with everything? Sienna Miller's favourite Gucci Brixton loafers are a sleek penny style that would be perfect for your workwear wardrobe. Made from the softest leather they feature gold-tone hardware and seam detail.
Vagabond Loafers
Vagabond Eyra Loafers
Sizes available: UK 3-8
Colours available: Black
Shipping: £5 Standard Delivery or free for orders over £65
Returns: Free within 14 days
Hailey Bieber's exact pair from Vagabond is still available to shop and now on sale. Made from smooth black leather, they feature a boxy square toe and detailed stitching along the upper. Hailey styled hers with wide-leg cargo trousers and a tee.
M&S Loafers
M&S Leather Trim Flat Loafers
Sizes available: UK 3-8
Colours available: Black
Shipping: £3.99 Standard Delivery or free for orders over £60
Returns: Free within 35 days
Marks & Spencer's trending loafers are bestsellers thanks to their likeness to a far more expensive Chloé pair. Made from real leather, they have a classic slip-on design and gold hardware, plus they feature the brand's signature foot-aligning Insolia Flex technology.
& Other Stories Loafers
& Other Stories Leather Penny Loafers
Sizes available: EUR 36-42
Colours available: Black, Mahogany
Shipping: £4 Standard Delivery or free for orders over £80
Returns: Free within 30 days
& Other Stories has one of the best collections of loafers on the high street. We love this classic Penny-style pair which is made from real leather with stitch details and a small heel.
H&M Loafers
H&M Loafers
Sizes available: UK 2-9
Colours available: Brown, Black
Shipping: £3.99 Standard Delivery or free for orders over £30
Returns: Free within 28 days
Looking for a pair of brown loafers? This pair from H&M is so affordable at under £30. They have a chunky rubber sole, a satin lining and feature rounded toes with a decorative tab at the front.
Grenson Loafers
Grenson Hattie Loafers
Sizes available: UK 3-8
Colours available: Black
Shipping: Free Express Delivery
Returns: Free within 28 days
Known for the iconic chunky boots, we're not surprised Grenson is a front runner for the high street's comfiest Prada-style loafers. Cut from smooth leather, the lug sole is surprisingly lightweight and trimmed at a slight angle to give a flared silhouette.
Charles & Keith Loafers
Charles & Keith Metallic Accent Loafers
Sizes available: UK 2-8
Colours available: Black, White, Olive Green, Dark Brown
Shipping: £4 Standard Delivery or free for orders over £50
Returns: Free within 28 days
Sienna Miller-favourite Charles & Keith has these loafers that mix a classic penny silhouette with a chunkier heel and feature a shiny gold metallic accent. They're also available in white, olive green and dark brown, to suit any style.
Josefinas Loafers
Josefinas Confidence Loafers
Sizes available: EUR 34-43
Colours available: Black
Shipping: £7 Standard Delivery or free for orders over £300
Returns: Free within 30 days
Josefinas beautiful leather loafers are handmade to order in Portugal - and they're so luxe. Featuring a sleek design with subtle gold hardwear and a small heel, the chic style will upgrade all of your outfits as we move into autumn/winter.
|
https://www.hellomagazine.com/shopping/512137/best-loafers-for-women/
| 2024-01-26T18:59:11Z
|
blocked_url
|
Vertex Energy (VTNR - Free Report) announced operational and financial outlook for the fourth quarter of 2023. The expected throughput volumes at the company’s Mobile, AL, refinery is 67,000 barrels per day, lower than the company’s previous guidance of 68,000-71,000. The slight reduction from the forecasted range is due to the effect of the strategic lowering of throughput volumes owing to deteriorating market conditions. The decline also stemmed from the previously disclosed downtime for replacing an electric transformer.
VTNR is set to release fourth-quarter results sometime in late February. The bottom-line estimate for the to-be-reported quarter is pegged at a loss of 6 cents per share on revenues of $816.7 million.
Fourth-Quarter Update
The company expects renewable diesel production of 3,900 barrels per day, just below the previously projected range of 4,000-6,000. Yield on renewable throughput volumes is now estimated at 96%, also below the previously predicted band of 97-98%.
Vertex also expects yield of finished conventional fuel products (gasoline, diesel and jet fuel etc.) to be in the range of 65-67% compared with the previously forecasted band of 64-68%. This demonstrates the benefit of yield optimization effects that were introduced in the second quarter of 2023.
The operating expenses are expected to be in the $3.75-$3.95 per barrel range. This shows a 5.5% improvement from the prior guidance at the midpoint. Capital expenditures for the fourth quarter are expected to be in the range of $8-$10 million. The projected range is 48.6% below the prior guidance.
Outlook for 2024
According to Vertex, since the beginning of the first quarter of 2024, it has been witnessing an improvement in crack rates and increased marginal efficiency. The company aims to use the positive market conditions to ramp up production for both conventional fuels as well as renewable diesel. The increased production capacity utilization is in line with evolving market conditions.
Recent Energy Earnings
While it's early in the earnings season, there have been a few key energy releases so far. Let’s take a look at some of them.
SLB(SLB - Free Report) , the largest oilfield contractor, announced fourth-quarter 2023 earnings of 86 cents per share (excluding charges and credits), which beat the Zacks Consensus Estimate of 84 cents. SLB’s bottom line also increased from the year-ago quarter’s level of 71 cents.
SLB’s strong quarterly earnings resulted from higher evaluation and stimulation activity in the international market. As of Dec 31, 2023, the company had approximately $4 billion in cash and short-term investments. It had a long-term debt of $10.8 billion at the end of 2023.
Smaller rival Halliburton (HAL - Free Report) reported fourth-quarter 2023 adjusted net income per share of 86 cents, which surpassed the Zacks Consensus Estimate of 80 cents. The figure was also well above the year-ago quarter’s level of 72 cents (adjusted). The outperformance reflects strength in the international markets, partly offset by weak performance in the North American region.
In good news for investors, Halliburton raised its quarterly dividend by 6.3% to 17 cents per share (or 68 cents per share annualized). It reported fourth-quarter capital expenditure of $399 million. As of Dec 31, 2023, the company had approximately $2.3 billion in cash/cash equivalents and $7.6 billion in long-term debt, representing a debt-to-capitalization ratio of 44.7.
Meanwhile, energy infrastructure provider Kinder Morgan (KMI - Free Report) reported fourth-quarter adjusted earnings per share of 28 cents, slightly below the Zacks Consensus Estimate of 31 cents. The bottom line was adversely affected by a decline in realized weighted natural gas liquid price and milder winter conditions observed in 2023. However, KMI’s fourth-quarter DCF was $1.2 billion, down $46 million from the year-ago quarter’s level.
As of Dec 31, 2023, Kinder Morgan reported $83 million in cash and cash equivalents. Its long-term debt amounted to $27.9 billion. In its initial budget for 2024, KMI set its adjusted EBITDA guidance of $8.2 billion. It also declared a dividend of $1.15 per share, indicating an increase from the prior-year figure of $1.13.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Schlumberger Limited (SLB) - free report >>
Halliburton Company (HAL) - free report >>
|
https://www.zacks.com/stock/news/2216445/vertex-vtnr-expects-reduced-throughput-volumes-in-q4-2023
| 2024-01-26T18:59:12Z
|
blocked_url
|
Incyte’s (INCY - Free Report) performance in 2023 was tepid as pipeline setbacks and competition for lead drug Jakafi weighed on shares.
Lead drug Jakafi (ruxolitinib) posted 8% growth in sales in the first three quarters of 2023.
However, the FDA approval of GSK plc’s (GSK - Free Report) momelotinib, under the brand name Ojjaara, for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythaemia), in adults with anemia, posed a concern.
Ojjaara is a once-a-day oral JAK1/JAK2 and activin A receptor type 1 inhibitor.
Incyte’s Jakafi, a first-in-class JAK1/JAK2 inhibitor, is also approved for myelofibrosis. The approval of another JAK1/JAK2 inhibitor for the same indication will pose competition for Jakafi, particularly given Ojjaara’s comprehensive labeling.
Ojjaara is approved for newly diagnosed and previously treated myelofibrosis patients with anemia that addresses the critical manifestations of the disease, namely anemia, constitutional symptoms and splenomegaly.
Incyte has a collaboration agreement with Swiss pharma giant Novartis (NVS - Free Report) for Jakafi.
Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi outside the country.
Earlier, Incyte suffered a setback when the FDA issued a complete response letter (“CRL”) for ruxolitinib extended-release tablets for once-daily use in the treatment of certain types of myelofibrosis, polycythemia vera and graft-versus-host disease.
The CRL stated that the FDA could not approve the new drug application (“NDA”) in its present form. The regulatory body acknowledged that the study submitted to the NDA met its objective of bioequivalence based on the area under the curve parameters but identified additional requirements for approval.
Incyte also discontinued the phase III LIMBER-304 trial, which evaluated the efficacy and safety of parsaclisib plus Jakafi versus placebo plus Jakafi in adult (age ≥18 years) patients with myelofibrosis who have an inadequate response to Jakafi monotherapy. The trial was discontinued following the results of a pre-planned interim analysis conducted by an independent data monitoring committee, indicating that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.
Nevertheless, the strong uptake of Opzelura (ruxolitinib) cream in atopic dermatitis (AD) and vitiligo in the United States propelled the company to post 9% revenue growth in the first three quarters.
Opzelura's solid uptake is being driven by patient demand growth and payer coverage expansion as the launch in AD and vitiligo continues. Opzelura was also approved in Europe for treating nonsegmental vitiligo with facial involvement. Moreover, three phase II studies in lichen planus, lichen sclerosus and mild to moderate hidradenitis suppurativa have completed enrollment. Two phase III trials evaluating ruxolitinib cream in prurigo nodularis are ongoing.
In addition, Incyte announced encouraging results from the phase III TRuE-AD3 study evaluating the safety and efficacy of Opzelura in children (age ≥2 to <12 years) with AD. A potential label expansion in this population will boost sales.
Incyte is also evaluating povorcitinib, an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. 52-week data from a phase IIb study evaluating the safety and efficacy of povorcitinib showed that treatment with oral povorcitinib was associated with substantial total body and facial repigmentation across all treatment groups at week 52 and further reinforces the efficacy profile and potential of povorcitinib as an oral treatment for patients with extensive nonsegmental vitiligo.
The phase II, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy and safety of povorcitinib in participants with prurigo nodularis (“PN”) met its primary endpoint. A phase III study in PN is being planned.
Earlier, the FDA also approved Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), for treating adults with metastatic or recurrent locally advanced merkel cell carcinoma.
Incyte has collaborated with Syndax for the development and commercialization of axatilimab, an anti-CSF-1R antibody; the biologics license application for axatilimab in adult and pediatric patients six years or older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy was submitted to the FDA on Dec 28, 2023. An approval is anticipated in 2024.
Approval of additional drugs will add incremental revenues to the top line and reduce the company’s dependence on Jakafi.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
GSK PLC Sponsored ADR (GSK) - free report >>
|
https://www.zacks.com/stock/news/2216446/incyte-incy-banks-on-opzelura-as-jakafi-faces-competition
| 2024-01-26T18:59:18Z
|
blocked_url
|
Gentex (GNTX - Free Report) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 13.64%. A quarter ago, it was expected that this maker of automatic-dimming rearview mirrors and other products would post earnings of $0.42 per share when it actually produced earnings of $0.45, delivering a surprise of 7.14%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Gentex
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Gentex shares have lost about 2.5% since the beginning of the year versus the S&P 500's gain of 2.6%.
What's Next for Gentex?
While Gentex has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Gentex: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.52 on $611.91 million in revenues for the coming quarter and $2.15 on $2.51 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Automotive - Original Equipment is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Modine (MOD - Free Report) , is yet to report results for the quarter ended December 2023. The results are expected to be released on January 30.
This heating and cooling products maker is expected to post quarterly earnings of $0.57 per share in its upcoming report, which represents a year-over-year change of +18.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Modine's revenues are expected to be $586.1 million, up 4.7% from the year-ago quarter.
|
https://www.zacks.com/stock/news/2216447/gentex-gntx-q4-earnings-and-revenues-top-estimates
| 2024-01-26T18:59:20Z
|
blocked_url
|
Norfolk Southern (NSC - Free Report) came out with quarterly earnings of $2.83 per share, missing the Zacks Consensus Estimate of $2.90 per share. This compares to earnings of $3.42 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -2.41%. A quarter ago, it was expected that this railroad would post earnings of $2.74 per share when it actually produced earnings of $2.65, delivering a surprise of -3.28%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Norfolk Southern
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Norfolk Southern shares have added about 0.6% since the beginning of the year versus the S&P 500's gain of 2.6%.
What's Next for Norfolk Southern?
While Norfolk Southern has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Norfolk Southern: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.96 on $3.08 billion in revenues for the coming quarter and $12.95 on $12.59 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Transportation - Rail is currently in the top 45% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Canadian Pacific Kansas City (CP - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2023. The results are expected to be released on January 30.
This railroad is expected to post quarterly earnings of $0.83 per share in its upcoming report, which represents a year-over-year change of +2.5%. The consensus EPS estimate for the quarter has been revised 1.8% lower over the last 30 days to the current level.
Canadian Pacific Kansas City's revenues are expected to be $2.71 billion, up 49.6% from the year-ago quarter.
|
https://www.zacks.com/stock/news/2216448/norfolk-southern-nsc-q4-earnings-and-revenues-miss-estimates
| 2024-01-26T18:59:26Z
|
blocked_url
|
Wall Street closed higher on Thursday, driven by encouraging economic data. The S&P 500 managed a record close for the fifth straight session. All of the major stock indexes ended in the green.
How Did the Benchmarks Perform?
The Dow Jones Industrial Average (DJI) rose 242.74 points, or 0.6%, to close at 38,049.13. Twenty-six components of the 30-stock index ended in positive territory, while four ended in negative.
The tech-heavy Nasdaq Composite gained 28.58 points, or 0.2%, to close at 15,510.50.
The S&P 500 added 25.61 points, or 0.5%, to close at 4,894.16. Nine of the 11 broad sectors of the benchmark index closed in the green. The Energy Select Sector SPDR (XLE), the Utilities Select Sector SPDR (XLU) and the Communication Services Select Sector SPDR (XLC) advanced 2.3%, 1.8% and 1.6%, respectively, while the Consumer Discretionary Select Sector SPDR (XLY) declined 1.2%.
The fear-gauge CBOE Volatility Index (VIX) increased 2.4% to 13.45. A total of 11.5 billion shares were traded on Thursday, in line with the last 20-session average. Advancing issues outnumbered the declining ones on the S&P 500 by a 4.0-to-one ratio. The S&P 500 recorded 50 new highs and two new lows, while the Nasdaq posted 97 new highs and 119 new lows.
The S&P 500 Records its Fifth Consecutive Peak
The S&P 500 recently hit its record high in over two years and has since sustained the momentum. On Thursday, the benchmark index closed the day on a fifth straight record high. Currently, market participants are keeping a keen watch on fourth-quarter earnings to gauge whether this momentum will continue.
U.S. Economy Grows Faster Than Expected
On the basis of strong consumer spending, the U.S. economy grew faster than expected in fourth-quarter 2023 and managed to keep at bay any murmurs about a recession that was dominating the markets while the Fed’s tight monetary policy regime was dragging on.
The advance fourth-quarter GDP report from the Commerce Department showed inflation pressures subsiding further. However, it also suggested that March might be too soon for the U.S. central bank to start cutting interest rates. GDP estimate for the quarter currently stands at a 3.3% increase compared to the consensus estimate of 2% for the period. The advance for the prior quarter remained unrevised at 4.9%. The market took kindly to the news and stocks broadly rallied.
Consequently, shares of Netflix, Inc. (NFLX - Free Report) and Caterpillar Inc. (CAT - Free Report) rose 3.1% and 3.5%, respectively. Netflix currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Economic Data
The Labor Department said on Thursday that initial jobless claims rose to 214,000, increasing 25,000 for the week ending Jan 20. The previous week's level was revised up by 2,000 from 187,000 to 189,000. The four-week moving average decreased to 202,250, marking a fall of 1,500 from the previous week. The prior week's average was revised up by 500 to 203,750.
Continuing claims came in at 1,833,000 for the week ending Jan 13, increasing 27,000 from the previous week’s unrevised level. The four-week moving average was 1,835,000, a decrease of 13,250 from the previous week's revised average. Last week's average was revised up by 250 from 1,848,000 to 1,848,250.
The U.S. Census Bureau reported that durable goods orders remained virtually unchanged for December. In November, they had gone up by 5.5%.
The U.S. Census Bureau and the U.S. Department of Housing and Urban Development jointly reported that new home sales for December had come in at 664,000. The number for November had been revised up to 615,000.
|
https://www.zacks.com/stock/news/2216449/stock-market-news-for-jan-26-2024
| 2024-01-26T18:59:33Z
|
blocked_url
|
This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.04% per year. These returns cover a period from January 1, 1988 through December 4, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by FIS.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
|
https://www.zacks.com/stock/news/2216451/company-news-for-jan-26-2024
| 2024-01-26T18:59:39Z
|
blocked_url
|
BP plc (BP - Free Report) anticipates that the Calypso deepwater natural gas field, located offshore Trinidad and Tobago, will receive approval for its final investment decision (FID) as early as the end of 2025, per a Reuters report.
BP, which holds a 30% stake in the Calypso discoveries, had previously projected that the FID could be made in 2026. However, David Campbell, the head of BP's Trinidad and Tobago operations, revealed that the company is expediting the process, working through the capital value process and gradually advancing through engineering stages. Campbell expressed optimism about a final investment decision within the next year or two.
Woodside Energy, the operator of the Calypso project, remains committed to advancing the deepwater endeavor. The project’s director, Stacy Patrick, emphasized the potential for unlocking significant natural gas reserves in Trinidad.
Per the report, Trinidad and Tobago's government has been urging operators, particularly offshore drillers, to expedite bringing gas discoveries to market due to shortages resulting from declining production. Energy minister Stuart Young announced that Calypso is expected to produce 700 million cubic feet per day of gas.
According to Campbell, BP's focus in Trinidad lies in deepwater exploration. The company has identified over 20 trillion cubic feet of gas and one billion barrels of oil in the Columbus basin, situated off the southeastern coast of Trinidad, near Venezuela. Currently, it is actively engaged in the development of gas projects in this region.
BP, the U.K.-headquartered energy giant, possesses a robust portfolio of upstream projects, supporting substantial production growth. Some other stocks for investors interested in the energy sector are Sunoco LP (SUN - Free Report) , Oceaneering International, Inc. (OII - Free Report) and Vaalco Energy, Inc. (EGY - Free Report) .
Sunoco is among the biggest motor fuel distributors in the U.S. wholesale market in terms of volumes. By distributing more than 10 fuel brands via 10,000 convenience stores under long-term distribution contracts, the partnership will continue to generate stable cash flow. Its distribution networks reflect a strong business with sustainable and predictable cash flow.
Oceaneering International is a leading provider of integrated technology solutions, active at all phases of the offshore oilfield lifecycle. Its strong relationship with high-quality customers provides revenue visibility and business certainty. OII is well-positioned to supply equipment for deep-water projects.
Vaalco Energy is an independent energy company involved in upstream operation business with a diversified presence in Africa and Canada. Having a large inventory of drilling locations in premium Canadian Acreage, the company’s production outlook seems bright.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
BP p.l.c. (BP) - free report >>
Sunoco LP (SUN) - free report >>
|
https://www.zacks.com/stock/news/2216452/bp-eyes-fid-for-trinidads-calypso-deepwater-gas-field-by-2025
| 2024-01-26T18:59:45Z
|
blocked_url
|
Johnson & Johnson (JNJ - Free Report) reported fourth-quarter and full-year 2024 results on Jan 23. The drug and medical devices giant beat the Zacks Consensus Estimate for both earnings as well as sales in the fourth quarter.
In August, J&J completely separated its Consumer Health business into a newly listed company called Kenvue (KVUE - Free Report) , which now operates as a separate and fully independent company.
After completion of the exchange offer, J&J now has a 9.5% stake (approximately 180 million shares) in Kenvue’s common stock, which it may monetize in a tax-efficient manner in 2024.
With the complete separation of the Consumer Health segment, J&J has now become a two-sector company focused on the Pharmaceutical and MedTech fields.
Here, we discuss some key takeaways from the fourth-quarter 2023 conference call.
J&J’s Innovative Medicines (previously referred to as Pharmaceutical) unit outperformed expectations, with sales of several key drugs like Darzalex, Stelara, Tremfya and Imbruvica beating estimates. Sales of all these drugs were driven by market share gains. Importantly, the delay in the launch of biosimilar versions of the blockbuster drug Stelara benefited J&J’s top line. In May, J&J settled its litigation with Amgen (AMGN - Free Report) , as a result of which J&J does not anticipate the launch of a biosimilar version of Stelara in the United States until January 2025.
In addition, the rapid adoption of new products such as Carvykti, Tecvayli, Talvey and Spravato also contributed to top-line growth. The sales growth was partially dampened by lower sales of Imbruvica, the COVID vaccine and generic/biosimilar competition to drugs like Zytiga and Remicade.
In 2024, J&J expects to record above-market growth in the Innovative Medicine unit, for the 13th consecutive quarter. The growth is expected to be driven by key products like Darzalex, Tremfya and Erleada and the rapid adoption of new products. Innovative Medicine sales growth is expected to be slightly stronger in the first half of the year compared to the second half due to the potential entry of Stelara biosimilars in Europe in mid-2024. In fact, J&J expects the Innovative Medicine business to grow 5% to 7% from 2025 to 2030.
The MedTech segment also beat the Zacks Consensus Estimate. Sales in the MedTech businesses continued to benefit from strong procedure recovery and new products, which were partially offset by international sanctions in Russia and volume-based procurement issues in China in some categories.
In 2024, in the MedTech segment, J&J expects operational sales growth to be relatively consistent. Procedure volumes are expected to be above pre-COVID levels, with a modest impact of Russia sanctions in the first half.
J&J re-confirmed its full-year adjusted earnings and sales growth guidance that it had issued in December. In 2024, J&J expects total revenues in the range of $87.8 billion-$88.6 billion, which indicates growth in the range of 4.5%-5.5%, driven by both its Innovative Medicine and MedTech segments. Operational sales growth is expected in the range of 5%-6%. Adjusted earnings per share are expected in the range of $10.55-$10.75. The earnings range implies growth in the range of 6.4%-8.4%.
Adjusted pretax operating margins are expected to improve approximately 50 basis points from 2023. However, J&J’s chief financial officer, Joseph Wolk, mentioned on the call that potential Stelara biosimilar launches in Europe in the second half and some lingering inflationary costs in the MedTech inventory are expected to hurt margins.
On the call, the company also mentioned that it had spent $3 billion for more than 50 smaller licensing partnerships or deals in 2023. Earlier this month, J&J announced a definitive agreement to acquire Ambrx Biopharma (AMAM - Free Report) for a total equity value of approximately $2.0 billion.
The acquisition will strengthen J&J’s oncology pipeline by adding Ambrx’s lead pipeline candidate, ARX517, a prostate-specific membrane antigen targeting antibody drug conjugate (ADC), being developed for metastatic castration-resistant prostate cancer. Ambrx is developing next-generation ADCs by leveraging its proprietary synthetic biology technology that effectively kills cancer cells and limits toxicities associated with chemotherapy treatment.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Johnson & Johnson (JNJ) - free report >>
Amgen Inc. (AMGN) - free report >>
|
https://www.zacks.com/stock/news/2216453/key-takeaways-from-jnjs-jnj-q4-earnings-presentation
| 2024-01-26T18:59:51Z
|
blocked_url
|
Truck transmission manufacturer Allison Transmission (ALSN - Free Report) has forged a strategic partnership with SANY, a leading global heavy equipment manufacturer in the mining and construction sectors. The collaboration positions Allison as a key supplier of transmissions for SANY's lineup of mining vehicles, including the next-generation SANY SKT105 wide body mining dump truck, rigid dump trucks and articulated dump trucks.
Per the terms of the agreement, Allison will supply its family of Off Road Series and Wide Body Dump Series transmissions for integration into SANY's fleet of mining vehicles.
Lu Shiwei, heavy commercial director at SANY, emphasized the importance of this collaboration in bolstering productivity and maneuverability, especially in the face of demanding duty-cycles and harsh mining conditions.
The deal aligns with Allison's broader objective of expanding its market presence in the mining dump truck segment across Africa, Asia and South America. By combining SANY's expertise in heavy equipment manufacturing with Allison's cutting-edge transmission technology, the collaboration promises to deliver unparalleled performance, reliability and productivity to mining operations worldwide. As the demand for high-performance mining vehicles continues to rise, this strategic partnership positions both companies for sustained growth and success in the global mining market.
Last week, Allison secured an $83.3 million contract to supply upgraded and new X1100 transmissions for the U.S. Army's Abrams Main Battle Tank variants and foreign military sales customers. The contract involves delivering these transmissions throughout 2024, aligning with the performance demands of the Abrams tank. The upgrade program integrates new components with existing customer hardware, providing a zero-mileage transmission for the Abrams System Enhancement Package version 3 tanks. This helps achieve significant cost savings.
Allison also announced the ratification of a new agreement with the International United Automobile, Aerospace, and Agricultural Implement Workers of America (UAW) Local 933. Covering approximately 1,600 UAW-represented employees in Indianapolis, IN, the four-year agreement, expiring on Nov 14, 2027, signifies a collaborative effort toward employee well-being and the company's future growth.
Allison is set to report its fourth-quarter 2023 results on Feb 13. The Zacks Consensus Estimate for ALSN’s quarterly sales and earnings per share is pegged at $754 million and $1.42, respectively. The company’s close peers include Oshkosh Corp. (OSK - Free Report) , Adient (ADNT - Free Report) and BorgWarner (BWA - Free Report) , among others.
Oshkosh is scheduled to report results on Jan 30. The consensus mark for OSK’s fourth-quarter sales and earnings is pegged at $2.47 billion and $2.17, respectively.
Adient is scheduled to report results on Feb 7. The consensus mark for ADNT’s sales and earnings for the to-be-reported quarter is pegged at $3.7 billion and 57 cents, respectively.
BorgWarner is scheduled to report results on Feb 8. The consensus mark for BWA’s fourth-quarter sales and earnings is pegged at $3.6 billion and 91 cents, respectively.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
BorgWarner Inc. (BWA) - free report >>
Allison Transmission Holdings, Inc. (ALSN) - free report >>
|
https://www.zacks.com/stock/news/2216454/allison-alsn-partners-sany-for-mining-transmission-solutions
| 2024-01-26T18:59:57Z
|
blocked_url
|
CureVac N.V. (CVAC - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 14.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.
How to Determine if a Stock is Oversold
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
Why CVAC Could Bounce Back Before Long
The heavy selling of CVAC shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 29.05. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.
The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for CVAC has increased 0.4%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, CVAC currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216455/down--1425-in-4-weeks-heres-why-you-should-you-buy-the-dip-in-curevac-nv-cvac
| 2024-01-26T19:00:03Z
|
blocked_url
|
Nouveau Monde Graphite Inc. (NMG - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 15.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.
How to Determine if a Stock is Oversold
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
Why NMG Could Bounce Back Before Long
The heavy selling of NMG shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 22.08. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.
The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for NMG has increased 2.1%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, NMG currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216456/after-plunging--1594-in-4-weeks-heres-why-the-trend-might-reverse-for-nouveau-monde-graphite-inc-nmg
| 2024-01-26T19:00:09Z
|
blocked_url
|
OneWater Marine (ONEW - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 20.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.
Guide to Identifying Oversold Stocks
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
Why ONEW Could Bounce Back Before Long
The heavy selling of ONEW shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 29.05. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.
This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering ONEW in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 2.7% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, ONEW currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2216457/down--2021-in-4-weeks-heres-why-onewater-marine-onew-looks-ripe-for-a-turnaround
| 2024-01-26T19:00:15Z
|
blocked_url
|
For the quarter ended December 2023, Logitech (LOGI - Free Report) reported revenue of $1.26 billion, down 1.1% over the same period last year. EPS came in at $1.53, compared to $1.14 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.23 billion, representing a surprise of +2.17%. The company delivered an EPS surprise of +36.61%, with the consensus EPS estimate being $1.12.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Logitech performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Gaming: $409.04 million versus $382.69 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change.
- Net Sales- Keyboards & Combos: $229.43 million compared to the $216.75 million average estimate based on four analysts. The reported number represents a change of +4.3% year over year.
- Net Sales- Pointing Devices: $206.18 million compared to the $210.44 million average estimate based on four analysts. The reported number represents a change of +3.6% year over year.
- Net Sales- Other: $49.44 million versus the four-analyst average estimate of $43.65 million. The reported number represents a year-over-year change of +3568%.
- Net Sales- Webcams: $85.85 million versus $91.09 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +46.8% change.
- Net Sales- Tablet Accessories: $64.24 million compared to the $71.16 million average estimate based on four analysts. The reported number represents a change of -1.4% year over year.
- Net Sales- Headsets: $41.76 million versus $45.95 million estimated by four analysts on average.
- Net Sales- Video Collaboration: $169.52 million compared to the $167.12 million average estimate based on four analysts. The reported number represents a change of -25.1% year over year.
Shares of Logitech have returned -9.8% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2216458/compared-to-estimates-logitech-logi-q3-earnings-a-look-at-key-metrics
| 2024-01-26T19:00:22Z
|
blocked_url
|
For the quarter ended December 2023, Stellar Bancorp (STEL - Free Report) reported revenue of $112.82 million, down 10.6% over the same period last year. EPS came in at $0.55, compared to $0.04 in the year-ago quarter.
The reported revenue represents a surprise of +4.72% over the Zacks Consensus Estimate of $107.73 million. With the consensus EPS estimate being $0.56, the EPS surprise was -1.79%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Stellar Bancorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net interest margin (tax equivalent): 4.4% versus the three-analyst average estimate of 4.2%.
- Efficiency Ratio: 69.2% compared to the 62% average estimate based on three analysts.
- Total nonperforming loans: $39.19 million compared to the $41.41 million average estimate based on two analysts.
- Average Balance - Total interest-earning assets: $9.58 billion compared to the $9.76 billion average estimate based on two analysts.
- Net charge-offs (recoveries) to average loans (annualized): 0.1% versus the two-analyst average estimate of 0.1%.
- Total nonperforming assets: $39.19 million versus $41.41 million estimated by two analysts on average.
- Net Interest Income: $105.93 million versus $102.97 million estimated by three analysts on average.
- Net Interest Income (tax equivalent): $106.12 million versus $103.17 million estimated by three analysts on average.
- Total Non-Interest Income: $6.89 million compared to the $4.70 million average estimate based on three analysts.
Shares of Stellar Bancorp have returned -6.9% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2216459/compared-to-estimates-stellar-bancorp-stel-q4-earnings-a-look-at-key-metrics
| 2024-01-26T19:00:28Z
|
blocked_url
|
For the quarter ended December 2023, Gentex (GNTX - Free Report) reported revenue of $589.13 million, up 19.3% over the same period last year. EPS came in at $0.50, compared to $0.37 in the year-ago quarter.
The reported revenue represents a surprise of +4.90% over the Zacks Consensus Estimate of $561.61 million. With the consensus EPS estimate being $0.44, the EPS surprise was +13.64%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Gentex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Auto-Dimming Mirror Shipments - Total Interior Mirrors: 7,478 thousand versus the two-analyst average estimate of 7,854.26 thousand.
- Auto-Dimming Mirror Shipments - Total Exterior Mirrors: 4,878 thousand compared to the 4,094.7 thousand average estimate based on two analysts.
- Auto-Dimming Mirror Shipments - Total Auto-Dimming Mirror Units: 12,357 thousand compared to the 11,948.96 thousand average estimate based on two analysts.
- Auto-Dimming Mirror Shipments - Total North American Mirror Units: 3,837 thousand compared to the 3,770.89 thousand average estimate based on two analysts.
- Auto-Dimming Mirror Shipments - International Exterior Mirrors: 3,109 thousand versus the two-analyst average estimate of 2,624.9 thousand.
- Auto-Dimming Mirror Shipments - North American Exterior Mirrors: 1,769 thousand versus 1,469.8 thousand estimated by two analysts on average.
- Auto-Dimming Mirror Shipments - Total International Mirror Units: 8,519 thousand versus 8,178.07 thousand estimated by two analysts on average.
- Auto-Dimming Mirror Shipments - International Interior Mirrors: 5,410 thousand versus 5,553.17 thousand estimated by two analysts on average.
- Auto-Dimming Mirror Shipments - North American Interior Mirrors: 2,068 thousand compared to the 2,301.1 thousand average estimate based on two analysts.
- Revenue- Other: $10.50 million compared to the $11.10 million average estimate based on three analysts.
- Revenue- Automotive Products: $578.70 million versus the three-analyst average estimate of $542.64 million.
Shares of Gentex have returned -3.3% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2216460/gentex-gntx-q4-earnings-how-key-metrics-compare-to-wall-street-estimates
| 2024-01-26T19:00:34Z
|
blocked_url
|
First Citizens BancShares (FCNCA - Free Report) reported $2.45 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 99.4%. EPS of $46.58 for the same period compares to $20.94 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.36 billion, representing a surprise of +3.93%. The company delivered an EPS surprise of -3.94%, with the consensus EPS estimate being $48.49.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how First Citizens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Interest Margin: 3.9% versus the four-analyst average estimate of 3.9%.
- Efficiency Ratio: 60.8% versus 50.2% estimated by four analysts on average.
- Net charge-off ratio: 0.5% versus 0.6% estimated by three analysts on average.
- Average Balance - Total interest-earning assets: $196.25 billion versus $194.98 billion estimated by three analysts on average.
- Total non-accrual loans: $969 million versus $893.34 million estimated by two analysts on average.
- Total Non Interest Income: $543 million versus the four-analyst average estimate of $522.74 million.
- Net Interest Income: $1.91 billion compared to the $1.89 billion average estimate based on four analysts.
- Rental income on operating lease equipment: $252 million compared to the $147.25 million average estimate based on three analysts.
- Service charges on deposit accounts: $44 million versus $44 million estimated by three analysts on average.
- Factoring commissions: $22 million versus the three-analyst average estimate of $21.18 million.
- Merchant services, net: $12 million versus the three-analyst average estimate of $12.67 million.
- Cardholder services, net: $36 million compared to the $41 million average estimate based on three analysts.
Shares of First Citizens have returned -1.8% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216461/compared-to-estimates-first-citizens-fcnca-q4-earnings-a-look-at-key-metrics
| 2024-01-26T19:00:40Z
|
blocked_url
|
BankUnited, Inc. (BKU - Free Report) reported $234.3 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 13.2%. EPS of $0.72 for the same period compares to $0.82 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $244.11 million, representing a surprise of -4.02%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.72.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how BankUnited, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net charge-offs to average loans: 0.1% versus the four-analyst average estimate of 0.1%.
- Net Interest Margin: 2.6% versus 2.6% estimated by four analysts on average.
- Average Interest-Earning Assets: $34.07 billion versus $34.09 billion estimated by four analysts on average.
- Deposit service charges and fees: $5.39 million versus $5.79 million estimated by four analysts on average.
- Net Interest Income (FTE basis): $221.44 million versus $221.83 million estimated by four analysts on average.
- Other non-interest income: $7.37 million versus the four-analyst average estimate of $5.36 million.
- Total Non-Interest Income: $17.09 million compared to the $25.45 million average estimate based on four analysts.
- Lease financing: $3.72 million compared to the $14.55 million average estimate based on four analysts.
- Net interest income before provision for loan losses: $217.21 million versus $217.68 million estimated by three analysts on average.
Shares of BankUnited, Inc. have returned -8.8% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2216462/bankunited-inc-bku-reports-q4-earnings-what-key-metrics-have-to-say
| 2024-01-26T19:00:47Z
|
blocked_url
|
For the quarter ended December 2023, Colgate-Palmolive (CL - Free Report) reported revenue of $4.95 billion, up 6.9% over the same period last year. EPS came in at $0.87, compared to $0.77 in the year-ago quarter.
The reported revenue represents a surprise of +1.06% over the Zacks Consensus Estimate of $4.9 billion. With the consensus EPS estimate being $0.85, the EPS surprise was +2.35%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Colgate-Palmolive performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Oral, Personal and Home Care- North America: $999 million compared to the $987.43 million average estimate based on five analysts. The reported number represents a change of +3.4% year over year.
- Net Sales- Oral, Personal and Home Care- Latin America: $1.19 billion compared to the $1.16 billion average estimate based on five analysts. The reported number represents a change of +17.9% year over year.
- Net Sales- Oral, Personal and Home Care- Africa/Eurasia: $262 million versus $241.15 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -4% change.
- Net Sales- Oral, Personal and Home Care- Europe: $685 million versus the five-analyst average estimate of $668.96 million. The reported number represents a year-over-year change of +10%.
- Net Sales- Oral, Personal and Home Care- Asia Pacific: $698 million compared to the $666.84 million average estimate based on five analysts. The reported number represents a change of +0.3% year over year.
- Net Sales- Pet Nutrition: $1.11 billion versus $1.16 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.
- Net Sales- Total Oral, Personal and Home Care: $3.84 billion versus the five-analyst average estimate of $3.72 billion. The reported number represents a year-over-year change of +7.5%.
- Operating profit- Total Oral, Personal and Home Care: $1.01 billion versus $978.54 million estimated by three analysts on average.
- Operating profit- Corporate: -$169 million versus the three-analyst average estimate of -$166.24 million.
- Operating profit- Pet Nutrition: $231 million compared to the $235.42 million average estimate based on three analysts.
Shares of Colgate-Palmolive have returned +2.5% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2216463/colgate-palmolive-cl-reports-q4-earnings-what-key-metrics-have-to-say
| 2024-01-26T19:00:53Z
|
blocked_url
|
For the quarter ended December 2023, South Plains Financial (SPFI - Free Report) reported revenue of $44.31 million, down 9.6% over the same period last year. EPS came in at $0.61, compared to $0.71 in the year-ago quarter.
The reported revenue represents a surprise of -6.23% over the Zacks Consensus Estimate of $47.25 million. With the consensus EPS estimate being $0.65, the EPS surprise was -6.15%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how South Plains Financial performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Efficiency ratio: 68.7% versus the two-analyst average estimate of 67.3%.
- Average Balance - Total interest-earning assets: $3.99 billion compared to the $4.07 billion average estimate based on two analysts.
- Nonperforming Loans: $5.18 million compared to the $5.76 million average estimate based on two analysts.
- Net Interest Margin (FTE): 3.5% compared to the 3.5% average estimate based on two analysts.
- Net charge-offs (recoveries) to average loans outstanding (annualized): 0.1% versus 0.1% estimated by two analysts on average.
- Net Interest Income: $35.16 million versus the two-analyst average estimate of $35.43 million.
- Net Interest Income (FTE): $35.39 million versus $35.54 million estimated by two analysts on average.
- Total Noninterest Income: $9.15 million versus $11.74 million estimated by two analysts on average.
Shares of South Plains Financial have returned -3.9% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216464/compared-to-estimates-south-plains-financial-spfi-q4-earnings-a-look-at-key-metrics
| 2024-01-26T19:00:59Z
|
blocked_url
|
For the quarter ended December 2023, Dime Community (DCOM - Free Report) reported revenue of $82.99 million, down 21.9% over the same period last year. EPS came in at $0.39, compared to $0.99 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $81.01 million, representing a surprise of +2.45%. The company delivered an EPS surprise of -18.75%, with the consensus EPS estimate being $0.48.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Dime Community performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Efficiency Ratio: 65% compared to the 62.9% average estimate based on two analysts.
- Net Interest Margin: 2.3% versus the two-analyst average estimate of 2.2%.
- Average Balance - Total interest-earning assets: $12.83 billion versus $12.89 billion estimated by two analysts on average.
- Total Non-Interest Income: $8.87 million versus $8.69 million estimated by two analysts on average.
- Net Interest Income: $74.12 million versus the two-analyst average estimate of $72.34 million.
Shares of Dime Community have returned -8.5% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2216465/dime-community-dcom-q4-earnings-taking-a-look-at-key-metrics-versus-estimates
| 2024-01-26T19:01:05Z
|
blocked_url
|
For the quarter ended December 2023, American Express (AXP - Free Report) reported revenue of $15.8 billion, up 11.5% over the same period last year. EPS came in at $2.62, compared to $2.07 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $16.03 billion, representing a surprise of -1.43%. The company delivered an EPS surprise of -1.13%, with the consensus EPS estimate being $2.65.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how American Express performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Card billed business (Network volumes): $434.4 billion compared to the $441.8 billion average estimate based on nine analysts.
- Total Card Member loans: $126 billion versus the eight-analyst average estimate of $124.55 billion.
- Worldwide cardmember loans - Average loans: $121.8 billion versus $121.66 billion estimated by seven analysts on average.
- Total Card Member receivables: $60.4 billion versus $60.3 billion estimated by seven analysts on average.
- Risk-Based Capital - Common Equity Tier 1: 10.5% versus the seven-analyst average estimate of 10.8%.
- Total cards-in-force: 141.2 million versus 140.48 million estimated by five analysts on average.
- Tier 1 Leverage Ratio: 9.9% versus the five-analyst average estimate of 10.4%.
- Tier 1 Ratio: 11.3% compared to the 11.1% average estimate based on five analysts.
- Total Capital Ratio: 13.1% versus the four-analyst average estimate of 13.2%.
- International Card service - Billed business: $88.1 billion versus $89.27 billion estimated by four analysts on average.
- Commercial Services - Billed business: $131.3 billion versus $133.28 billion estimated by four analysts on average.
- Basic cards-in-force: 118.7 million versus 119.3 million estimated by four analysts on average.
Shares of American Express have returned +0.1% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216466/american-express-axp-reports-q4-earnings-what-key-metrics-have-to-say
| 2024-01-26T19:01:12Z
|
blocked_url
|
For the quarter ended December 2023, Autoliv, Inc. (ALV - Free Report) reported revenue of $2.75 billion, up 17.8% over the same period last year. EPS came in at $3.74, compared to $1.83 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $2.75 billion, representing a surprise of +0.19%. The company delivered an EPS surprise of +15.08%, with the consensus EPS estimate being $3.25.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Autoliv, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales - Airbags, Steering Wheels and Other - Organic change: 16% compared to the 6.9% average estimate based on three analysts.
- Sales - Seatbelt Products - Organic change: 15% versus the three-analyst average estimate of 22.8%.
- Sales by Segment - Organic change: 16% versus 11.1% estimated by two analysts on average.
- Sales- Seatbelt Products: $887 million versus $977.37 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +17.6% change.
- Sales- Airbags, Steering Wheels and Other: $1.86 billion versus the three-analyst average estimate of $1.73 billion. The reported number represents a year-over-year change of +17.9%.
Shares of Autoliv, Inc. have returned -6.7% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216467/autoliv-inc-alv-reports-q4-earnings-what-key-metrics-have-to-say
| 2024-01-26T19:01:18Z
|
blocked_url
|
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about CrowdStrike Holdings (CRWD - Free Report) .
CrowdStrike currently has an average brokerage recommendation (ABR) of 1.14, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 42 brokerage firms. An ABR of 1.14 approximates between Strong Buy and Buy.
Of the 42 recommendations that derive the current ABR, 38 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 90.5% and 4.8% of all recommendations.
Brokerage Recommendation Trends for CRWD
Check price target & stock forecast for CrowdStrike here>>>
The ABR suggests buying CrowdStrike, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
ABR Should Not Be Confused With Zacks Rank
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Should You Invest in CRWD?
In terms of earnings estimate revisions for CrowdStrike, the Zacks Consensus Estimate for the current year has increased 0.4% over the past month to $2.95.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for CrowdStrike. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for CrowdStrike may serve as a useful guide for investors.
|
https://www.zacks.com/stock/news/2216468/brokers-suggest-investing-in-crowdstrike-crwd-read-this-before-placing-a-bet
| 2024-01-26T19:01:24Z
|
blocked_url
|
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about McDonald's (MCD - Free Report) .
McDonald's currently has an average brokerage recommendation (ABR) of 1.60, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 31 brokerage firms. An ABR of 1.60 approximates between Strong Buy and Buy.
Of the 31 recommendations that derive the current ABR, 20 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 64.5% and 9.7% of all recommendations.
Brokerage Recommendation Trends for MCD
Check price target & stock forecast for McDonald's here>>>
The ABR suggests buying McDonald's, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
ABR Should Not Be Confused With Zacks Rank
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Should You Invest in MCD?
In terms of earnings estimate revisions for McDonald's, the Zacks Consensus Estimate for the current year has increased 0.2% over the past month to $11.80.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for McDonald's. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for McDonald's may serve as a useful guide for investors.
|
https://www.zacks.com/stock/news/2216469/wall-street-analysts-think-mcdonalds-mcd-is-a-good-investment-is-it?
| 2024-01-26T19:01:30Z
|
blocked_url
|
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Royal Caribbean (RCL - Free Report) .
Royal Caribbean currently has an average brokerage recommendation (ABR) of 1.44, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 16 brokerage firms. An ABR of 1.44 approximates between Strong Buy and Buy.
Of the 16 recommendations that derive the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 6.3% of all recommendations.
Brokerage Recommendation Trends for RCL
Check price target & stock forecast for Royal Caribbean here>>>
The ABR suggests buying Royal Caribbean, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
ABR Should Not Be Confused With Zacks Rank
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Should You Invest in RCL?
In terms of earnings estimate revisions for Royal Caribbean, the Zacks Consensus Estimate for the current year has increased 0.4% over the past month to $6.62.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Royal Caribbean. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for Royal Caribbean may serve as a useful guide for investors.
|
https://www.zacks.com/stock/news/2216470/brokers-suggest-investing-in-royal-caribbean-rcl-read-this-before-placing-a-bet
| 2024-01-26T19:01:36Z
|
blocked_url
|
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Let's take a look at what these Wall Street heavyweights have to say about JPMorgan Chase & Co. (JPM - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
JPMorgan Chase & Co. currently has an average brokerage recommendation (ABR) of 1.59, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 23 brokerage firms. An ABR of 1.59 approximates between Strong Buy and Buy.
Of the 23 recommendations that derive the current ABR, 15 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 65.2% and 8.7% of all recommendations.
Brokerage Recommendation Trends for JPM
Check price target & stock forecast for JPMorgan Chase & Co. here>>>
While the ABR calls for buying JPMorgan Chase & Co., it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
ABR Should Not Be Confused With Zacks Rank
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is JPM Worth Investing In?
In terms of earnings estimate revisions for JPMorgan Chase & Co., the Zacks Consensus Estimate for the current year has increased 1.5% over the past month to $15.74.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for JPMorgan Chase & Co. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for JPMorgan Chase & Co. may serve as a useful guide for investors.
|
https://www.zacks.com/stock/news/2216471/is-it-worth-investing-in-jpmorgan-chase-co-jpm-based-on-wall-streets-bullish-views?
| 2024-01-26T19:01:43Z
|
blocked_url
|
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Let's take a look at what these Wall Street heavyweights have to say about Amazon (AMZN - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Amazon currently has an average brokerage recommendation (ABR) of 1.11, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 46 brokerage firms. An ABR of 1.11 approximates between Strong Buy and Buy.
Of the 46 recommendations that derive the current ABR, 42 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 91.3% and 6.5% of all recommendations.
Brokerage Recommendation Trends for AMZN
Check price target & stock forecast for Amazon here>>>
While the ABR calls for buying Amazon, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
ABR Should Not Be Confused With Zacks Rank
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is AMZN Worth Investing In?
In terms of earnings estimate revisions for Amazon, the Zacks Consensus Estimate for the current year has increased 1.6% over the past month to $2.70.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Amazon. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for Amazon may serve as a useful guide for investors.
|
https://www.zacks.com/stock/news/2216472/amazon-amzn-is-considered-a-good-investment-by-brokers-is-that-true?
| 2024-01-26T19:01:49Z
|
blocked_url
|
From a technical perspective, Coherent (COHR - Free Report) is looking like an interesting pick, as it just reached a key level of support. COHR recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
The 50-day simple moving average is a widely used technical indicator that helps determine support or resistance levels for different types of securities. It's one of three major moving averages, but takes precedent because it's the first sign of an up or down trend.
COHR has rallied 6.5% over the past four weeks, and the company is a Zacks Rank #3 (Hold) at the moment. This combination suggests COHR could be on the verge of another move higher.
The bullish case only gets stronger once investors take into account COHR's positive earnings estimate revisions. There have been 1 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.
Investors should think about putting COHR on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.
|
https://www.zacks.com/stock/news/2216473/coherent-cohr-crossed-above-the-50-day-moving-average-what-that-means-for-investors
| 2024-01-26T19:02:03Z
|
blocked_url
|
Electronic Arts (EA - Free Report) is set to report third-quarter fiscal 2024 results on Jan 30.
For third-quarter fiscal 2024, EA expects GAAP revenues between $1.825 billion and $2.025 billion and diluted earnings in the range of $0.75-$1.01 per share.
For the quarter, the Zacks Consensus Estimate for earnings has remained steady at $2.91 per share in the past 30 days. The figure indicates 7.38% growth from the year-ago quarter’s reported figure.
The consensus mark for revenues is pegged at $2.39 billion, suggesting a 1.86% increase from the year-ago quarter’s reported figure.
The company’s earnings beat the Zacks Consensus Estimate thrice in the trailing four quarters and missed once, the average surprise being 12.95%.
Let’s see how things have shaped up for this announcement.
Factors to Consider
Steady demand for EA’s digital and live services across its portfolio is expected to have aided active user growth in the fiscal third quarter.
In the to-be-reported quarter, Electronic Arts announced the release of EA SPORTS NHL 24, the latest installment of the hockey game. EA also launched EA SPORTS WRC, the official game of the FIA World Rally Championship.
EA SPORTS UFC 5, the latest game of the martial arts franchise, was also released in the to-be-reported quarter.
Moreover, an increase in active users after the release of blockbuster games like EA SPORTS FIFA and Apex Legends is expected to have boosted net bookings growth in the to-be-reported quarter. Apex Legends Season 18 drove greater-than-anticipated player acquisition and monetization in the fiscal second quarter. The momentum is likely to have continued in the to-be-reported quarter.
On Oct 6, EA announced strong engagement of players in its EA SPORTS FC ecosystem, including both EA SPORTS FC 24 and EA SPORTS FC Mobile, in the first week after its launch.
Net bookings for the fiscal second quarter were $1.82 billion, up 3.8% year over year or 5% in constant currency.
The company expects net bookings between $2.25 billion and $2.45 billion in the fiscal third quarter of 2024. The Zacks Consensus Estimate for bookings is currently pegged at $2.383 billion, indicating a rise of 1.8% year over year.
EA's strength in Live Services in mobile game franchises, such as Battlefield 2042, It Takes Two, Madden Mobile, FIFA Mobile, Tetris, Star Wars: Galaxy of Heroes and The Lord of the Rings: The Return of the King is expected to have positively impacted the top line.
In the to-be-reported quarter, EA announced the launch of EA SPORTS FC Tactical, a new mobile game that focuses on turn-based strategy.
However, the company has been witnessing increased operating expenses for game development and marketing. The rising expenses are expected to have kept margins under pressure in the to-be-reported quarter.
Sluggishness in video game spending in the quarter is expected to have reflected in EA’s top-line growth. Per VentureBeat, which cited NPD data on consumer spending on video games, video game spending declined 5% in October and 7% in November. For the month of December, video game sales remained mostly even, with a slight 4% increase in total sales.
What Our Model Says
Per the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.
EA currently has an Earnings ESP of -2.65% and carries a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Here are some stocks worth considering, as our model shows that these have the right combination of elements to beat on earnings this season.
Apple (AAPL - Free Report) has an Earnings ESP of +2.13% and a Zacks Rank #3 at present. You can see the complete list of today's Zacks #1 Rank stocks here.
Apple is scheduled to release first-quarter fiscal 2024 results on Feb 1. The Zacks Consensus Estimate for AAPL’s earnings is pegged at $2.08 per share, suggesting a jump of 10.6% from the prior-year quarter.
A. O. Smith (AOS - Free Report) has an Earnings ESP of +3.80% and a Zacks Rank #3 at present.
A. O. Smith is set to report its fourth-quarter 2023 results on Jan 30. The Zacks Consensus Estimate for AOS’ earnings is pegged at 95 cents per share, suggesting growth of 10.5% from the prior-year period’s reported figure.
Alphabet (GOOGL - Free Report) has an Earnings ESP of +2.26% and a Zacks Rank #3 at present.
Alphabet is scheduled to release its fourth-quarter 2023 results on Jan 30. The Zacks Consensus Estimate for GOOGL’s earnings is pinned at $1.62 per share, indicating growth of 54.3% from the year-ago quarter.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Apple Inc. (AAPL) - free report >>
A. O. Smith Corporation (AOS) - free report >>
|
https://www.zacks.com/stock/news/2216476/electronic-arts-ea-to-report-q3-earnings-whats-in-store?
| 2024-01-26T19:02:09Z
|
blocked_url
|
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value Score
For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank
A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Parker-Hannifin (PH - Free Report)
Parker-Hannifin Corporation is a global diversified manufacturer of motion & control technologies and systems. The company provides precision engineered solutions for a wide variety of mobile, industrial and aerospace markets.
PH is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. PH has a Growth Style Score of B, forecasting year-over-year earnings growth of 7.8% for the current fiscal year.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.11 to $23.24 per share. PH boasts an average earnings surprise of 11.8%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, PH should be on investors' short list.
|
https://www.zacks.com/stock/news/2216477/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick?-this-1-stock-could-be-the-perfect-pick
| 2024-01-26T19:02:15Z
|
blocked_url
|
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value Score
For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank
A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Accenture (ACN - Free Report)
Years of investment in digital, cloud and security strategy has helped Accenture evolve as a trusted and viable consulting services provider. It is currently one of the top consultancy firms of the world by revenues that increased 4% in fiscal 2023 with a contribution of 52% from consulting services.
ACN is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. ACN has a Growth Style Score of B, forecasting year-over-year earnings growth of 4.7% for the current fiscal year.
Six analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.02 to $12.22 per share. ACN boasts an average earnings surprise of 5.9%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, ACN should be on investors' short list.
|
https://www.zacks.com/stock/news/2216478/accenture-acn-is-a-top-ranked-growth-stock-should-you-buy?
| 2024-01-26T19:02:21Z
|
blocked_url
|
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth Score
Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum Score
Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM Score
What if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Atmos Energy (ATO - Free Report)
Founded in 1906, Atmos Energy Corporation, along with its subsidiaries, is engaged in regulated natural gas distribution and storage business. The company serves nearly 3.3 million customers in more than 1,400 communities in eight states from the Blue Ridge Mountains in the East to the Rocky Mountains in the West. The company operates more than 73,000 miles of transmission and distribution lines as well as 5,700 miles of interstate pipelines. Atmos Energy’s pipelines are connected to 37 different pipelines across eight states, thereby providing supplier diversity.
ATO is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. ATO has a Growth Style Score of B, forecasting year-over-year earnings growth of 7.7% for the current fiscal year.
Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.07 to $6.57 per share. ATO also boasts an average earnings surprise of 1.1%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, ATO should be on investors' short list.
|
https://www.zacks.com/stock/news/2216479/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick?-this-1-stock-could-be-the-perfect-pick
| 2024-01-26T19:02:28Z
|
blocked_url
|
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Halozyme Therapeutics (HALO - Free Report)
San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.
HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. HALO has a Growth Style Score of B, forecasting year-over-year earnings growth of 24.4% for the current fiscal year.
For fiscal 2023, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.03 to $2.75 per share. HALO boasts an average earnings surprise of 5.8%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, HALO should be on investors' short list.
|
https://www.zacks.com/stock/news/2216483/halozyme-therapeutics-halo-is-a-top-ranked-growth-stock-should-you-buy?
| 2024-01-26T19:02:34Z
|
blocked_url
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum Score
Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Planet Fitness (PLNT - Free Report)
Planet Fitness, headquartered in Hampton, NH, was formed in 1992. It is one of the leading franchisors and operators of fitness centers in the United States. As of Sep 30, 2023, the company had more than 18.5 million members and 2,498 stores in all 50 states of the United States, the District of Columbia, Puerto Rico, Canada, Panama, Mexico and Australia. As of Dec 31, 2022, about 98% of all franchise stores were owned and operated by a franchisee group.
PLNT is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. PLNT has a Growth Style Score of A, forecasting year-over-year earnings growth of 34.8% for the current fiscal year.
One analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0 to $2.21 per share. PLNT also boasts an average earnings surprise of 7.4%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, PLNT should be on investors' short list.
|
https://www.zacks.com/stock/news/2216484/heres-why-planet-fitness-plnt-is-a-strong-growth-stock
| 2024-01-26T19:02:40Z
|
blocked_url
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: MasterCard (MA - Free Report)
Founded in 1966 and headquartered in Purchase, NY, Mastercard Inc. is a leading global payment solutions company that provides an array of services in support of credit, debit, mobile, web-based and contactless payments, and other related electronic payment programs to financial institutions and other entities.
MA is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. MA has a Growth Style Score of B, forecasting year-over-year earnings growth of 14.3% for the current fiscal year.
For fiscal 2023, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $12.17 per share. MA boasts an average earnings surprise of 3.6%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, MA should be on investors' short list.
|
https://www.zacks.com/stock/news/2216485/heres-why-mastercard-ma-is-a-strong-growth-stock
| 2024-01-26T19:02:47Z
|
blocked_url
|
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One stock to keep an eye on is Panasonic (PCRFY - Free Report) . PCRFY is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock holds a P/E ratio of 8.96, while its industry has an average P/E of 16.81. Over the past 52 weeks, PCRFY's Forward P/E has been as high as 15.53 and as low as 8.80, with a median of 11.46.
Investors should also recognize that PCRFY has a P/B ratio of 0.71. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. PCRFY's current P/B looks attractive when compared to its industry's average P/B of 1.92. PCRFY's P/B has been as high as 1.01 and as low as 0.66, with a median of 0.83, over the past year.
Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. PCRFY has a P/S ratio of 0.35. This compares to its industry's average P/S of 0.56.
Finally, investors will want to recognize that PCRFY has a P/CF ratio of 4.69. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. PCRFY's current P/CF looks attractive when compared to its industry's average P/CF of 6.74. Over the past year, PCRFY's P/CF has been as high as 5.66 and as low as 4.15, with a median of 4.50.
These are just a handful of the figures considered in Panasonic's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that PCRFY is an impressive value stock right now.
|
https://www.zacks.com/stock/news/2216489/should-value-investors-buy-panasonic-pcrfy-stock?
| 2024-01-26T19:02:53Z
|
blocked_url
|
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One stock to keep an eye on is The RMR Group (RMR - Free Report) . RMR is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock holds a P/E ratio of 13.41, while its industry has an average P/E of 23.17. Over the past 52 weeks, RMR's Forward P/E has been as high as 15.38 and as low as 10.10, with a median of 12.76.
Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. RMR has a P/S ratio of 0.86. This compares to its industry's average P/S of 1.28.
Finally, investors should note that RMR has a P/CF ratio of 6.28. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. RMR's P/CF compares to its industry's average P/CF of 8.19. Within the past 12 months, RMR's P/CF has been as high as 23.11 and as low as 5.12, with a median of 6.57.
These are just a handful of the figures considered in The RMR Group's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that RMR is an impressive value stock right now.
|
https://www.zacks.com/stock/news/2216490/are-investors-undervaluing-the-rmr-group-rmr-right-now?
| 2024-01-26T19:02:59Z
|
blocked_url
|
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One company value investors might notice is The Gap (GPS - Free Report) . GPS is currently sporting a Zacks Rank of #1 (Strong Buy), as well as an A grade for Value.
Investors should also recognize that GPS has a P/B ratio of 2.86. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks solid versus its industry's average P/B of 3.88. Over the past 12 months, GPS's P/B has been as high as 3.31 and as low as 1.25, with a median of 1.73.
Finally, investors should note that GPS has a P/CF ratio of 12.27. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 13.07. GPS's P/CF has been as high as 16.24 and as low as 5.38, with a median of 8.01, all within the past year.
These figures are just a handful of the metrics value investors tend to look at, but they help show that The Gap is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, GPS feels like a great value stock at the moment.
|
https://www.zacks.com/stock/news/2216491/is-the-gap-gps-a-great-value-stock-right-now?
| 2024-01-26T19:03:05Z
|
blocked_url
|
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One company value investors might notice is Reliance Steel & Aluminum Co. (RS - Free Report) . RS is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock is trading with a P/E ratio of 14.78, which compares to its industry's average of 15.67. Over the past 52 weeks, RS's Forward P/E has been as high as 14.90 and as low as 11.15, with a median of 13.28.
Finally, investors should note that RS has a P/CF ratio of 10.02. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. RS's P/CF compares to its industry's average P/CF of 28.74. Over the past year, RS's P/CF has been as high as 10.14 and as low as 6.19, with a median of 8.93.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Reliance Steel & Aluminum Co. Is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, RS feels like a great value stock at the moment.
|
https://www.zacks.com/stock/news/2216492/should-value-investors-buy-reliance-steel-aluminum-co-rs-stock?
| 2024-01-26T19:03:12Z
|
blocked_url
|
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One company value investors might notice is EuroDry (EDRY - Free Report) . EDRY is currently sporting a Zacks Rank of #1 (Strong Buy), as well as an A grade for Value.
Investors should also recognize that EDRY has a P/B ratio of 0.54. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks solid versus its industry's average P/B of 1.42. Over the past 12 months, EDRY's P/B has been as high as 0.55 and as low as 0.35, with a median of 0.40.
Finally, investors should note that EDRY has a P/CF ratio of 4.25. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 5.82. EDRY's P/CF has been as high as 4.33 and as low as 1.01, with a median of 1.89, all within the past year.
If you're looking for another solid Transportation - Shipping value stock, take a look at Pangaea Logistics Solutions (PANL - Free Report) . PANL is a # 1 (Strong Buy) stock with a Value score of A.
Pangaea Logistics Solutions sports a P/B ratio of 1.12 as well; this compares to its industry's price-to-book ratio of 1.42. In the past 52 weeks, PANL's P/B has been as high as 1.12, as low as 0.65, with a median of 0.78.
These are just a handful of the figures considered in EuroDry and Pangaea Logistics Solutions's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that EDRY and PANL is an impressive value stock right now.
|
https://www.zacks.com/stock/news/2216493/should-value-investors-buy-eurodry-edry-stock?
| 2024-01-26T19:03:18Z
|
blocked_url
|
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One company to watch right now is Axis Capital Holdings (AXS - Free Report) . AXS is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A.
AXS is also sporting a PEG ratio of 1.22. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. AXS's industry currently sports an average PEG of 2.56. Over the past 52 weeks, AXS's PEG has been as high as 1.76 and as low as 1.13, with a median of 1.30.
Another notable valuation metric for AXS is its P/B ratio of 1.11. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks solid versus its industry's average P/B of 1.54. AXS's P/B has been as high as 1.31 and as low as 1, with a median of 1.06, over the past year.
Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. AXS has a P/S ratio of 0.9. This compares to its industry's average P/S of 1.17.
Finally, investors will want to recognize that AXS has a P/CF ratio of 7.93. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 9.17. AXS's P/CF has been as high as 17.12 and as low as 7.23, with a median of 10.92, all within the past year.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Axis Capital Holdings is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, AXS feels like a great value stock at the moment.
|
https://www.zacks.com/stock/news/2216494/are-investors-undervaluing-axis-capital-holdings-axs-right-now?
| 2024-01-26T19:03:24Z
|
blocked_url
|
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
YPF Sociedad Anonima (YPF - Free Report) is a stock many investors are watching right now. YPF is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock holds a P/E ratio of 4.21, while its industry has an average P/E of 8.61. Over the past 52 weeks, YPF's Forward P/E has been as high as 4.48 and as low as 2.18, with a median of 3.37.
Another valuation metric that we should highlight is YPF's P/B ratio of 0.58. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 1.18. YPF's P/B has been as high as 0.63 and as low as 0.34, with a median of 0.45, over the past year.
Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. YPF has a P/S ratio of 0.38. This compares to its industry's average P/S of 0.54.
Finally, we should also recognize that YPF has a P/CF ratio of 1.50. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 4.23. Within the past 12 months, YPF's P/CF has been as high as 1.62 and as low as 0.70, with a median of 1.01.
These figures are just a handful of the metrics value investors tend to look at, but they help show that YPF Sociedad Anonima is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, YPF feels like a great value stock at the moment.
|
https://www.zacks.com/stock/news/2216495/is-ypf-sociedad-anonima-ypf-stock-undervalued-right-now?
| 2024-01-26T19:03:30Z
|
blocked_url
|
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
ClevelandCliffs (CLF - Free Report) is a stock many investors are watching right now. CLF is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock has a Forward P/E ratio of 8.14. This compares to its industry's average Forward P/E of 11.19. Over the past 52 weeks, CLF's Forward P/E has been as high as 17.73 and as low as 6.12, with a median of 8.29.
Finally, we should also recognize that CLF has a P/CF ratio of 7.01. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 21.77. Over the past 52 weeks, CLF's P/CF has been as high as 8.11 and as low as 3.82, with a median of 6.16.
These are only a few of the key metrics included in ClevelandCliffs's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, CLF looks like an impressive value stock at the moment.
|
https://www.zacks.com/stock/news/2216496/should-value-investors-buy-clevelandcliffs-clf-stock?
| 2024-01-26T19:03:36Z
|
blocked_url
|
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One company to watch right now is Sappi (SPPJY - Free Report) . SPPJY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock is trading with a P/E ratio of 8.09, which compares to its industry's average of 10.86. Over the last 12 months, SPPJY's Forward P/E has been as high as 9.72 and as low as 5, with a median of 7.21.
Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. SPPJY has a P/S ratio of 0.22. This compares to its industry's average P/S of 0.54.
Finally, we should also recognize that SPPJY has a P/CF ratio of 2.35. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 5.02. Over the past year, SPPJY's P/CF has been as high as 2.82 and as low as 1.51, with a median of 2.15.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Sappi is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, SPPJY feels like a great value stock at the moment.
|
https://www.zacks.com/stock/news/2216497/should-value-investors-buy-sappi-sppjy-stock?
| 2024-01-26T19:03:43Z
|
blocked_url
|
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One company to watch right now is Centene (CNC - Free Report) . CNC is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock is trading with a P/E ratio of 11.13, which compares to its industry's average of 15.63. Over the last 12 months, CNC's Forward P/E has been as high as 12.02 and as low as 9.31, with a median of 10.44.
Investors will also notice that CNC has a PEG ratio of 0.95. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CNC's PEG compares to its industry's average PEG of 1.20. Over the past 52 weeks, CNC's PEG has been as high as 1.01 and as low as 0.71, with a median of 0.87.
We should also highlight that CNC has a P/B ratio of 1.59. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 3.67. Within the past 52 weeks, CNC's P/B has been as high as 1.79 and as low as 1.29, with a median of 1.48.
Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. CNC has a P/S ratio of 0.26. This compares to its industry's average P/S of 0.51.
Finally, we should also recognize that CNC has a P/CF ratio of 10.76. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 14.54. Over the past year, CNC's P/CF has been as high as 15.57 and as low as 8.17, with a median of 10.76.
These are only a few of the key metrics included in Centene's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, CNC looks like an impressive value stock at the moment.
|
https://www.zacks.com/stock/news/2216498/are-investors-undervaluing-centene-cnc-right-now?
| 2024-01-26T19:03:49Z
|
blocked_url
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Kroger (KR - Free Report)
The Kroger Co., which operates in the thin-margin grocery industry, has been undergoing a complete makeover, not only with respect to products but also in terms of the way consumers prefer shopping grocery. The company is focusing on plant-based products as well as eyeing technological expansion. It acquired meal kit company Home Chef and partnered with British online grocery delivery firm Ocado that reinforces its position in the online ordering, automated fulfillment and home delivery space. It has also introduced grocery delivery service Kroger Ship and inked a deal with driverless car company Nuro.
KR is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 10.17; value investors should take notice.
For fiscal 2024, seven analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.04 to $4.56 per share. KR boasts an average earnings surprise of 6.4%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, KR should be on investors' short list.
|
https://www.zacks.com/stock/news/2216500/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?-this-1-stock-could-be-the-perfect-pick
| 2024-01-26T19:03:55Z
|
blocked_url
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: TE Connectivity (TEL - Free Report)
TE Connectivity manufactures and designs products that connect and protect the flow of power and data inside millions of products used by consumers and industries.
TEL is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 19.49; value investors should take notice.
For fiscal 2024, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.02 to $7.40 per share. TEL boasts an average earnings surprise of 5%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, TEL should be on investors' short list.
|
https://www.zacks.com/stock/news/2216501/why-te-connectivity-tel-is-a-top-value-stock-for-the-long-term
| 2024-01-26T19:04:01Z
|
blocked_url
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AutoZone (AZO - Free Report)
AutoZone, Inc. is one of the leading specialty retailers and distributors of automotive replacement parts and accessories in the United States. It operates in the Do-It-Yourself (DIY) retail, Do-It-for-Me (DIFM) auto parts and products markets. At the end of fiscal 2023, the company had 6,300 stores in the United States, 740 in Mexico and 100 in Brazil. The total store count was 7,140 as of Aug 26, 2023. Each store offers wide-ranging products for cars, sport utility vehicles, vans and light trucks, including new and remanufactured automotive hard parts, maintenance items, accessories and non-automotive products.
AZO is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 18.26; value investors should take notice.
For fiscal 2024, 10 analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $2.64 to $150.51 per share. AZO boasts an average earnings surprise of 8.9%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, AZO should be on investors' short list.
|
https://www.zacks.com/stock/news/2216502/heres-why-autozone-azo-is-a-strong-value-stock
| 2024-01-26T19:04:07Z
|
blocked_url
|
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank
A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Lamb Weston (LW - Free Report)
Based in Eagle, ID, Lamb Weston Holdings, Inc. is a leading global manufacturer, marketer and distributor of value-added frozen potato products, particularly French fries, and also provides a range of appetizers.
LW is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 17.68; value investors should take notice.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.10 to $5.94 per share. LW boasts an average earnings surprise of 28.8%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, LW should be on investors' short list.
|
https://www.zacks.com/stock/news/2216507/why-lamb-weston-lw-is-a-top-value-stock-for-the-long-term
| 2024-01-26T19:04:14Z
|
blocked_url
|
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: EnerSys (ENS - Free Report)
Headquartered in Pennsylvania, EnerSys engages in manufacturing, marketing and distribution of various industrial batteries. Additionally, the company develops battery chargers and accessories, power equipment and outdoor cabinet enclosures. This apart, it provides support services for clients.
ENS is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 11.3; value investors should take notice.
For fiscal 2024, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.94 to $8.59 per share. ENS boasts an average earnings surprise of 10.4%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, ENS should be on investors' short list.
|
https://www.zacks.com/stock/news/2216508/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?-this-1-stock-could-be-the-perfect-pick
| 2024-01-26T19:04:24Z
|
blocked_url
|
The Business Services group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. GigaCloud Technology Inc. (GCT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Business Services sector should help us answer this question.
GigaCloud Technology Inc. is a member of the Business Services sector. This group includes 313 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GigaCloud Technology Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for GCT's full-year earnings has moved 33.9% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, GCT has moved about 27.3% on a year-to-date basis. Meanwhile, the Business Services sector has returned an average of 23.2% on a year-to-date basis. As we can see, GigaCloud Technology Inc. is performing better than its sector in the calendar year.
Another Business Services stock, which has outperformed the sector so far this year, is Getaround, Inc. (GETR - Free Report) . The stock has returned 32.7% year-to-date.
Over the past three months, Getaround, Inc.'s consensus EPS estimate for the current year has increased 16.1%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, GigaCloud Technology Inc. belongs to the Technology Services industry, which includes 174 individual stocks and currently sits at #66 in the Zacks Industry Rank. Stocks in this group have gained about 47.9% so far this year, so GCT is slightly underperforming its industry this group in terms of year-to-date returns. Getaround, Inc. is also part of the same industry.
Investors with an interest in Business Services stocks should continue to track GigaCloud Technology Inc. and Getaround, Inc. These stocks will be looking to continue their solid performance.
|
https://www.zacks.com/stock/news/2216511/is-gigacloud-technology-inc-gct-outperforming-other-business-services-stocks-this-year?
| 2024-01-26T19:04:31Z
|
blocked_url
|
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Abbott (ABT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Abbott is a member of our Medical group, which includes 1075 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Abbott is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABT's full-year earnings has moved 0.2% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ABT has gained about 2.2% so far this year. Meanwhile, the Medical sector has returned an average of -1.4% on a year-to-date basis. This means that Abbott is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Akoya Biosciences (AKYA - Free Report) . The stock is up 2.3% year-to-date.
In Akoya Biosciences' case, the consensus EPS estimate for the current year increased 24.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Abbott belongs to the Medical - Products industry, which includes 96 individual stocks and currently sits at #154 in the Zacks Industry Rank. Stocks in this group have gained about 4.2% so far this year, so ABT is slightly underperforming its industry this group in terms of year-to-date returns.
On the other hand, Akoya Biosciences belongs to the Medical - Biomedical and Genetics industry. This 521-stock industry is currently ranked #95. The industry has moved -13.4% year to date.
Abbott and Akoya Biosciences could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
|
https://www.zacks.com/stock/news/2216512/is-abbott-laboratories-abt-stock-outpacing-its-medical-peers-this-year?
| 2024-01-26T19:04:37Z
|
blocked_url
|
Investors interested in Consumer Staples stocks should always be looking to find the best-performing companies in the group. Colgate-Palmolive (CL - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Consumer Staples sector should help us answer this question.
Colgate-Palmolive is a member of our Consumer Staples group, which includes 193 different companies and currently sits at #14 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Colgate-Palmolive is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CL's full-year earnings has moved 1.4% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, CL has gained about 1.9% so far this year. Meanwhile, the Consumer Staples sector has returned an average of -5.7% on a year-to-date basis. This means that Colgate-Palmolive is outperforming the sector as a whole this year.
One other Consumer Staples stock that has outperformed the sector so far this year is Kerry Group PLC (KRYAY - Free Report) . The stock is up 0% year-to-date.
In Kerry Group PLC's case, the consensus EPS estimate for the current year increased 3.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Colgate-Palmolive belongs to the Soap and Cleaning Materials industry, which includes 7 individual stocks and currently sits at #202 in the Zacks Industry Rank. Stocks in this group have gained about 4.9% so far this year, so CL is slightly underperforming its industry this group in terms of year-to-date returns.
On the other hand, Kerry Group PLC belongs to the Food - Miscellaneous industry. This 45-stock industry is currently ranked #185. The industry has moved -5.8% year to date.
Colgate-Palmolive and Kerry Group PLC could continue their solid performance, so investors interested in Consumer Staples stocks should continue to pay close attention to these stocks.
|
https://www.zacks.com/stock/news/2216513/is-colgatepalmolive-cl-outperforming-other-consumer-staples-stocks-this-year?
| 2024-01-26T19:04:43Z
|
blocked_url
|
Badger Meter (BMI - Free Report) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.60 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 5%. A quarter ago, it was expected that this manufacturer of products that measure gas and water flow would post earnings of $0.76 per share when it actually produced earnings of $0.88, delivering a surprise of 15.79%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Badger Meter
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Badger Meter shares have lost about 1.3% since the beginning of the year versus the S&P 500's gain of 2.6%.
What's Next for Badger Meter?
While Badger Meter has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Badger Meter: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.76 on $178.32 million in revenues for the coming quarter and $3.34 on $746.13 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Instruments - Control is currently in the top 16% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Transcat, Inc. (TRNS - Free Report) , is yet to report results for the quarter ended December 2023. The results are expected to be released on January 29.
This company is expected to post quarterly earnings of $0.35 per share in its upcoming report, which represents a year-over-year change of +66.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Transcat, Inc.'s revenues are expected to be $63.36 million, up 10.4% from the year-ago quarter.
|
https://www.zacks.com/stock/news/2216516/badger-meter-bmi-beats-q4-earnings-and-revenue-estimates
| 2024-01-26T19:04:49Z
|
blocked_url
|
Denali Therapeutics Inc. (DNLI - Free Report) develops therapies targeting neurodegenerative diseases. The company owns an impressive pipeline of targeted therapeutic candidates for neurodegenerative diseases. Its recent pipeline progress has been encouraging.
Denali’s strategic partnerships with bigwigs like Biogen (BIIB - Free Report) and Sanofi (SNY - Free Report) provide funds for pipeline development.
Denali and Biogen are developing BIIB122/DNL151, a small-molecule inhibitor, of LRRK2 for Parkinson’s disease (“PD”).
Earlier this month, Denali outlined key milestones related to its pipeline development that it looks to achieve through 2024.
The phase IIb LUMA study, which is being conducted by BIIB, is evaluating BIIB122/DNL151 in early-stage PD with and without LRRK2 mutations and is expected to progress.
Denali has partnered with Sanofi to develop SAR443820/DNL788 in amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”) indications.
Sanofi plans to announce top-line data from the phase II HIMALAYA study, evaluating SAR443820/DNL788 for treating ALS, in the first half of 2024. The K2 phase II study on SAR443820/DNL788 in MS is expected to continue.
Meanwhile, eclitasertib (SAR443122/DNL758), which is being solely developed by SNY, is being evaluated in a phase II study for treating ulcerative colitis.
This apart, Denali’s wholly-owned candidates in late-stage development programs include tividenofusp alfa (DNL310) for treating MPS II (Hunter syndrome) and DNL343 for treating ALS.
The company plans to complete enrollment in the phase II/III COMPASS study investigating tividenofusp alfa in MPS II in 2024.
DNLI also aims to complete the enrollment of participants in regimen G (DNL343) of the phase II/III HEALEY ALS Platform study in 2024.
Denali does not have any approved products in its portfolio yet, and hence, any pipeline setback will be detrimental to its growth prospects. Also, the neurodegenerative field is characterized by intense and increasing competition. Denali’s high dependence on its partners for financial resources remains an overhang.
|
https://www.zacks.com/stock/news/2216518/denalis-dnli-pipeline-progresses-despite-stiff-competition
| 2024-01-26T19:04:56Z
|
blocked_url
|
The U.S. economy exhibited a robust performance in the fourth quarter of 2023, with the real Gross Domestic Product (GDP) expanding at an annualized rate of 3.3%, according to the Bureau of Economic Analysis' (BEA) initial estimate. This growth exceeded market expectations of 2% and followed a 4.9% increase in the third quarter.
That said, some specific areas of the ETF industry will likely benefit from solid GDP numbers. ETFs like SPDR S&P Retail ETF (XRT - Free Report) , iShares U.S. Industrials ETF (IYJ - Free Report) , SPDR Dow Jones REIT ETF (RWR - Free Report) , Financial Select Sector SPDR Fund (XLF - Free Report) and Vanguard Small-Cap Growth ETF (VBK - Free Report) are expected to outperform.
GDP Price Index and Core PCE
The report detailed that the Gross Domestic Product Price Index was recorded at 1.5% in the fourth quarter, a decrease from the previous quarter's 3.3%. Additionally, the Core Personal Consumption Expenditures (PCE) Price Index maintained a steady rise of 2% on a quarterly basis, aligning with prior quarter figures and market predictions.
Positive Outlook on Economic Growth
U.S. Treasury Secretary Janet Yellen expressed optimism regarding the fourth quarter's economic growth. She emphasized that the strong growth, coupled with a core inflation rate at 2%—the Federal Reserve's target—indicated healthy spending and productivity gains without exacerbating inflationary pressures.
ETFs to Benefit
SPDR S&P Retail ETF (XRT - Free Report) ) – Zacks Rank #2 (Buy)
Solid economic growth will have a positive impact on the consumer discretionary and retail sectors, which attract a major portion of consumer spending. The underlying S&P Retail Select Industry Index represents the retail sub-industry portion of the S&P TMI. The fund charges 35 bps in fees.
iShares U.S. Industrials ETF (IYJ - Free Report) ) – Zacks Rank #2
A rise in activity in the economy and the resultant uptick in business investments will fuel growth in the industrial sector, which makes IYJ appealing. The underlying Russell 1000 Industrials 40 Act 15/22.5 Daily Capped Index measures the performance of the industrial sector of the U.S. equity market. It includes: construction & materials, aerospace & defense, general industrials, electronic & electrical equipment, industrial engineering, industrial transportation & support services. The Index is capitalization-weighted. The fund charges 40 bps in fees.
SPDR Dow Jones REIT ETF (RWR - Free Report) ) – Zacks Rank #2
Rebounding residential investment will benefit the real estate sector.A contained inflation level should lead the Fed to hold on to its interest rate policy. The underlying Dow Jones U.S. Select REIT Index provides a measure of real estate securities that serve as proxies for direct real estate investing, in part by excluding securities whose value is not always closely tied to the value of the underlying real estate. The fund charges 25 bps in fees and yields 3.90% annually.
Financial Select Sector SPDR Fund (XLF - Free Report) ) – Zacks Rank #1 (Strong Buy)
A robust economy can lead to more investments and financial activities. The ultra-popular Financial Select Sector SPDR Fund ETF seeks to provide exposure to about 70 companies in diversified financial services, insurance, banks, capital markets, mortgage real estate investment trusts, consumer finance, and thrifts and mortgage finance industries. It charges investors 10 bps in fees per year.
Vanguard Small-Cap Growth ETF (VBK - Free Report) ) – Zacks Rank #1
Small-cap stocks generally lead the way higher on improving American economic health as these are closely tied to the U.S. economy and generate most of their revenues from the domestic market.VBK, which tracks the CRSP US Small Cap Growth Index, appears to be an excellent choice.
The underlying CRSP U.S. Small Cap Growth Index measures the investment return of small-capitalization growth stocks. The fund charges 7 bps in fees.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Financial Select Sector SPDR ETF (XLF) - free report >>
SPDR S&P Retail ETF (XRT) - free report >>
iShares U.S. Industrials ETF (IYJ) - free report >>
|
https://www.zacks.com/stock/news/2216519/us-gdp-growth-beats-expectations-in-q4-etfs-to-benefit
| 2024-01-26T19:05:04Z
|
blocked_url
|
Intuitive Surgical (ISRG - Free Report) announced that it has submitted an application for FDA 510(k) clearance of its next-generation da Vinci 5 multiport surgical robot.
The company’s da Vinci robotic surgical system family will include the new da Vinci 5, as well as the X and Xi systems with multiple ports and the SP system with one port. It also has Ion, a robotic-assisted device for lung biopsy with minimal invasion. The addition of the next-generation da Vinci 5 will be a significant addition to its portfolio.
The company expects an approval soon, which will be followed by a launch later this year.
More on the News
On its fourth-quarter earnings call, Intuitive Surgical announced that it has successfully completed a thorough IDE trial for the da Vinci 5 in multiple centers, according to Guthart. The trial enrolled patients until May 2023, and ISRG applied for 510(k) approval in August 2023. The company is currently answering FDA’s queries. In addition, Intuitive Surgical is also discussing the approval pathway for da Vinci 5 with regulators in Japan and South Korea.
Investors have been eagerly waiting for ISRG’s new da Vinci system. The company's shares lost a year ago as there was no announcement of any new multiport system in 2023.
Intuitive Surgical is preparing to manufacture da Vinci 5. The company has moved X system production to its Atlanta hub. Xi system production will also go to Atlanta this year. The company said it will open new plants in California for da Vinci 5 and Ion in the next 18 months. It will also finish moving Ion and SP lines to Mexicali, Mexico.
Comparison With Peers
Another company from the same industry, Masimo (MASI - Free Report) , won a favorable court ruling in its intellectual property dispute with tech-titan, Apple (AAPL - Free Report) over blood oxygen sensors in newer Apple Watch models.
Per the latest ruling in the ongoing patent dispute litigation, Apple has to stop selling watches with the oxygen measurement feature while an appeal of the ban plays out. Masimo sued Apple in 2020 when the latter added a blood oxygen sensor to its watches, starting with Series 6. Following a three-year-long battle, Masimo received its first favorable ruling against Apple.
DexCom (DXCM - Free Report) , another company in the same industry, unveiled its new state-of-the-art manufacturing facility in Athenry. With the ability to produce millions of Dexcom rtCGM sensors annually, the new plant will contribute to the betterment of diabetes patients throughout Europe, the Middle East and Africa (EMEA). Dexcom's first manufacturing plant in Europe will guarantee product flow throughout EMEA, potentially reducing goods costs and improving sustainability by cutting down on transit delivery times.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Apple Inc. (AAPL) - free report >>
Intuitive Surgical, Inc. (ISRG) - free report >>
|
https://www.zacks.com/stock/news/2216520/intuitive-surgical-isrg-seeks-fda-nod-for-next-gen-da-vinci-5
| 2024-01-26T19:05:05Z
|
blocked_url
|
The price trend for Bank7 (BSVN - Free Report) has been bearish lately and the stock has lost 7.6% over the past four weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.
While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this company is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.
Understanding Hammer Chart and the Technique to Trade It
This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'
In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.
When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.
Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.
Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.
Here's What Makes the Trend Reversal More Likely for BSVN
An upward trend in earnings estimate revisions that BSVN has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. That's because empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
The consensus EPS estimate for the current year has increased 0.1% over the last 30 days. This means that the Wall Street analysts covering BSVN are majorly in agreement about the company's potential to report better earnings than what they predicted earlier.
If this is not enough, you should note that BSVN currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Moreover, the Zacks Rank has proven to be an excellent timing indicator, helping investors identify precisely when a company's prospects are beginning to improve. So, for the shares of Bank7, a Zacks Rank of 2 is a more conclusive fundamental indication of a potential turnaround.
|
https://www.zacks.com/stock/news/2216522/bears-are-losing-control-over-bank7-bsvn-heres-why-its-a-buy-now
| 2024-01-26T19:05:11Z
|
blocked_url
|
Shares of Profound Medical (PROF - Free Report) have gained 5.5% over the past four weeks to close the last trading session at $8.28, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.75 indicates a potential upside of 66.1%.
The mean estimate comprises five short-term price targets with a standard deviation of $4.67. While the lowest estimate of $8 indicates a 3.4% decline from the current price level, the most optimistic analyst expects the stock to surge 129.5% to reach $19. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
But, for PROF, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Here's What You Should Know About Analysts' Price Targets
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in PROF
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current year, one estimate has moved higher over the last 30 days compared to no negative revision. As a result, the Zacks Consensus Estimate has increased 0.9%.
Moreover, PROF currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, while the consensus price target may not be a reliable indicator of how much PROF could gain, the direction of price movement it implies does appear to be a good guide.
|
https://www.zacks.com/stock/news/2216523/how-much-upside-is-left-in-profound-medical-prof-wall-street-analysts-think-6606?-wall-street-analysts-think-66.06
| 2024-01-26T19:05:25Z
|
blocked_url
|
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores?
The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Ameriprise Financial Services (AMP - Free Report)
Headquartered in Minneapolis, MN, Ameriprise Financial, Inc. was founded in 1894 under the name Investors Syndicate. Notably, since 2005-end, Ameriprise has been operating independently of American Express Company. As of Sep 30, 2023, the company owned, managed and administered assets worth $1.23 trillion.
AMP is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Finance stock. AMP has a Momentum Style Score of A, and shares are up 2.7% over the past four weeks.
For fiscal 2024, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.52 to $33.91 per share. AMP boasts an average earnings surprise of 1.5%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, AMP should be on investors' short list.
|
https://www.zacks.com/stock/news/2216524/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick?-this-1-stock-could-be-the-perfect-pick
| 2024-01-26T19:05:32Z
|
blocked_url
|
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores?
The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth Score
Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum Score
Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM Score
If you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank
A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Alkermes (ALKS - Free Report)
Dublin, Ireland-based Alkermes plc was formed by the Sep 2011 merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), the drug delivery unit of Elan Corporation, plc. Elan was acquired by Perrigo in 2013. The combined entity is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products to address unmet medical needs of patients in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis.
ALKS is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Medical stock. ALKS has a Momentum Style Score of B, and shares are up 0.5% over the past four weeks.
For fiscal 2023, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.03 to $1.58 per share. ALKS boasts an average earnings surprise of 93.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, ALKS should be on investors' short list.
|
https://www.zacks.com/stock/news/2216526/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick?-this-1-stock-could-be-the-perfect-pick
| 2024-01-26T19:05:38Z
|
blocked_url
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.